<SEC-DOCUMENT>0001628280-20-013679.txt : 20200917
<SEC-HEADER>0001628280-20-013679.hdr.sgml : 20200917
<ACCEPTANCE-DATETIME>20200916202400
ACCESSION NUMBER:		0001628280-20-013679
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20200915
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200917
DATE AS OF CHANGE:		20200916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		201179889

	BUSINESS ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		2489609009

	MAIL ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rmti-20200915.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:e7c61a3a-ab90-4f6d-83a6-780a6ceb1f1e,g:5f5e7233-c5fd-4f3c-a1b5-51621a270ca9,d:bce84512c8bf453590e96b3648a668ea--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rmti-20200915</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV80L2ZyYWc6ZWZmOThiNGJjMWRjNDc1Yjk0OWRiM2Y5OTE0MTRmMWQvdGFibGU6MTY4MTM3YjBmNjk1NDgzM2FkOGU5NGJkNDA0NThkZWIvdGFibGVyYW5nZToxNjgxMzdiMGY2OTU0ODMzYWQ4ZTk0YmQ0MDQ1OGRlYl8xLTEtMS0xLTA_78875133-66ad-4c35-b220-7215b7804c8c">0001041024</ix:nonNumeric><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV80L2ZyYWc6ZWZmOThiNGJjMWRjNDc1Yjk0OWRiM2Y5OTE0MTRmMWQvdGFibGU6MTY4MTM3YjBmNjk1NDgzM2FkOGU5NGJkNDA0NThkZWIvdGFibGVyYW5nZToxNjgxMzdiMGY2OTU0ODMzYWQ4ZTk0YmQ0MDQ1OGRlYl8yLTEtMS0xLTA_cc8eacc3-90ed-4dc0-8bef-853309126c40">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rmti-20200915.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibce84512c8bf453590e96b3648a668ea_1"></div><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM&#160;<ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU1_09fe5671-14a0-42cb-ab84-c4cad611d2bb">8-K</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CURRENT REPORT</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">the Securities Exchange Act of 1934</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date of Report (Date of earliest event reported): </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;<ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMzc_7daa98b9-751b-45bc-b8b2-f186f95b81fb">September 15, 2020</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU4_99e9c7fc-90d8-4449-a55b-9b3b11ad9685">ROCKWELL MEDICAL,&#160;INC.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:31.744%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:33.064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.892%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MWJiY2NjZTRjZGEyNDBmNDhmMWNlOTc1NWEzMmIxNTEvdGFibGVyYW5nZToxYmJjY2NlNGNkYTI0MGY0OGYxY2U5NzU1YTMyYjE1MV8wLTAtMS0xLTA_143d8cf9-09d9-4ea3-8ab3-a7708448eefb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MWJiY2NjZTRjZGEyNDBmNDhmMWNlOTc1NWEzMmIxNTEvdGFibGVyYW5nZToxYmJjY2NlNGNkYTI0MGY0OGYxY2U5NzU1YTMyYjE1MV8wLTEtMS0xLTA_6883eddd-208f-48b4-8334-a92c5979156c">000-23661</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MWJiY2NjZTRjZGEyNDBmNDhmMWNlOTc1NWEzMmIxNTEvdGFibGVyYW5nZToxYmJjY2NlNGNkYTI0MGY0OGYxY2U5NzU1YTMyYjE1MV8wLTItMS0xLTA_a125958f-6489-40e3-9bec-3e08fc2319f0">38-3317208</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Commission File Number)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU5_d44d5b5d-8dbd-48dc-996d-701441cbfcec">411 Hackensack Avenue, Suite&#160;501</ix:nonNumeric>, <ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU2_57d0cdf0-0993-45f8-958f-d042c5ff7510">Hackensack</ix:nonNumeric>, <ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTYw_7fd06ed4-4a90-411d-b69e-780bf5c9381b">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTYx_948df709-4886-4ada-affa-49dc72472e31">07601</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTYy_58b13ec5-3f42-43a2-af7e-c73883e24467">248</ix:nonNumeric>) <ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU3_f4e3ff11-97dd-43be-9be2-a440666e0b50">960-9009</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Not Applicable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Former name or former address, if changed since last report)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:454.50pt;"><tr><td style="width:1.0pt;"></td><td style="width:7.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:13.00pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:427.75pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6NzQ5M2UyYzJiNzI2NDQwYmE4NWRiNmM2MmM0MzcwZGUvdGFibGVyYW5nZTo3NDkzZTJjMmI3MjY0NDBiYTg1ZGI2YzYyYzQzNzBkZV8wLTEtMS0xLTA_e96d30a0-3bf4-4124-937b-7a1d161c6384">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:454.50pt;"><tr><td style="width:1.0pt;"></td><td style="width:7.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:13.00pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:427.75pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6NjhhNmM2YjM0YmIxNDMwZmIxMmM2OTUyNmY2M2RlNTkvdGFibGVyYW5nZTo2OGE2YzZiMzRiYjE0MzBmYjEyYzY5NTI2ZjYzZGU1OV8wLTEtMS0xLTA_31b59ede-1a20-4122-9d2f-07f9ed1848ab">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt;"><tr><td style="width:1.0pt;"></td><td style="width:7.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:13.00pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:484.75pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MGZlYTFhZTg1YjMwNDBlZWE4NGY3OWEwOTc4YzU5NDUvdGFibGVyYW5nZTowZmVhMWFlODViMzA0MGVlYTg0Zjc5YTA5NzhjNTk0NV8wLTEtMS0xLTA_c9585c35-ec24-4fc3-92d5-ff06758e562a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt;"><tr><td style="width:1.0pt;"></td><td style="width:7.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:13.00pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:484.75pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6YzQ1ZDQwNzdiMDU2NGRjZTk1NGFmNzQ4ZGVmYTlhYWYvdGFibGVyYW5nZTpjNDVkNDA3N2IwNTY0ZGNlOTU0YWY3NDhkZWZhOWFhZl8wLTEtMS0xLTA_770898d2-61d9-4a50-b795-b8ddfb29930d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:33.504%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.419%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.507%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.419%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:33.651%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#160;of&#160;Each&#160;Class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading&#160;Symbol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#160;of&#160;Each&#160;exchange&#160;on&#160;which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MTc4MzI0YThlZjUzNGZiODk4NDg0ZjhmZWZlMDg1ZDIvdGFibGVyYW5nZToxNzgzMjRhOGVmNTM0ZmI4OTg0ODRmOGZlZmUwODVkMl8xLTAtMS0xLTA_9938153c-c1bf-41ce-b332-8ba5df113d0d">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MTc4MzI0YThlZjUzNGZiODk4NDg0ZjhmZWZlMDg1ZDIvdGFibGVyYW5nZToxNzgzMjRhOGVmNTM0ZmI4OTg0ODRmOGZlZmUwODVkMl8xLTItMS0xLTA_c3ba7c37-273d-4955-ae06-f0b3966b669d">RMTI</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MTc4MzI0YThlZjUzNGZiODk4NDg0ZjhmZWZlMDg1ZDIvdGFibGVyYW5nZToxNzgzMjRhOGVmNTM0ZmI4OTg0ODRmOGZlZmUwODVkMl8xLTQtMS0xLTA_54d03a3c-cca6-444c-888d-2af203964152">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Emerging growth company&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTYz_4daacbf2-25ec-4847-8193-fb559bdc5103">&#9744;</ix:nonNumeric> </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.789%;"><tr><td style="width:1.0%;"></td><td style="width:8.722%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.376%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:86.502%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Item 5.02</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On September 15, 2020, Rockwell Medical, Inc. (the &#8220;Company&#8221;) announced the appointment of Russell L. Skibsted as the Company&#8217;s Executive Vice President, Chief Financial Officer and Chief Business Officer effective September 15, 2020 (the &#8220;Commencement Date&#8221;). Mr. Skibsted will also serve as the Company&#8217;s Principal Financial Officer.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Mr. Skibsted, age 61, most recently served as Chief Financial Officer of AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on cell therapy targeting the diseases of aging that was spun out of BioTime, Inc. (currently Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX)), from July 2017 to May 2020. Previously, Mr. Skibsted served as Chief Financial Officer of BioTime, Inc., a clinical-stage biotechnology company, from November 2015 to January 2019, where he simultaneously, from time to time, performed the role of Chief Financial Officer for several of BioTime&#8217;s public and private subsidiaries, including Agex Therapeutics, OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer and a former subsidiary of BioTime, Inc., from November 2015 until November 2017, and Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine with clinical programs in spinal cord injury and oncology immunotherapy and a former subsidiary of BioTime, Inc., from March 2016 until November 2016.  Mr. Skibsted served as Chief Financial Officer of Proove Biosciences, Inc., a private, commercial-stage personalized medicine company, from 2014 to November 2015. Mr. Skibsted was Managing Director of RSL Ventures, where he provided financial consulting services to public and private companies in the life sciences sector from 2013 to 2014. Mr. Skibsted served as Senior Vice President, Chief Financial Officer and Secretary of Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, from 2010 to 2013, and was Senior Vice President and Chief Business Officer of Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, from 2006 to 2009. From 2004 to 2006, Mr. Skibsted served as Chief Financial Officer of Hana Biosciences, Inc. and from 2000 to 2004 he served as Chief Financial Officer and Portfolio Management Partner of Asset Management Company, one of the first venture capital firms in the Silicon Valley. Mr. Skibsted holds a B.A. in Economics from Claremont McKenna College and an MBA from the Stanford Graduate School of Business.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On September 15, 2020, in connection with Mr. Skibsted&#8217;s commencement of employment, the Company entered into an employment agreement with Mr. Skibsted (the &#8220;Employment Agreement&#8221;). The Employment Agreement provides that Mr. Skibsted will serve as an at-will employee. Mr. Skibsted will receive an annualized base salary of $460,000 (&#8220;Base Salary&#8221;) and is eligible to receive performance-based bonuses of $75,000 and $50,000 subject to Mr. Skibsted&#8217;s continuous employment by the Company through the six month anniversary of the Commencement Date and the twelve month anniversary of the Commencement Date, respectively, and the fulfillment of certain conditions as set forth in the Employment Agreement. Mr. Skibsted will be eligible to earn year-end performance bonuses with a target bonus opportunity of 60% of his Base Salary (&#8220;Target Bonus&#8221;) commencing in 2021 and is eligible to participate in the employee benefit plans and programs generally available to the Company&#8217;s similarly situated senior executives. Mr. Skibsted is also eligible to receive annual long-term incentive grants consistent with similar practices for the Company&#8217;s senior executives, awarded at the discretion of the Compensation Committee of the board of directors. In connection with his commencement of employment, he received an initial equity grant comprised of a time-based option to purchase up to 600,000 shares of the Company&#8217;s common stock (the &#8220;Initial Time-Based Options&#8221;) and a performance-based option to purchase up to 150,000 shares of the Company&#8217;s common stock (the &#8220;Initial Performance-Based Options&#8221;). The Initial Time-Based Options and the Initial Performance-Based Options are issued outside of the Company&#8217;s stockholder-approved Amended and Restated 2018 Long-Term Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Employment Agreement, upon a termination of Mr. Skibsted&#8217;s employment due to death or Disability, any equity awards held by Mr. Skibsted subject to time-based vesting conditions will accelerate and become fully vested and the Initial Performance-Based Options, to the extent outstanding as of the date of such termination, will accelerate and become exercisable, if at all, in accordance with the terms of the award agreement evidencing such Initial Performance-Based Options. All stock options held by Mr. Skibsted that are exercisable as of the date of such termination, including any stock options that accelerate in connection with such termination, will remain exercisable until the earlier of one year following such termination and the expiration date of the stock options.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Employment Agreement, upon a termination of Mr. Skibsted&#8217;s employment by the Company without Cause or by Mr. Skibsted for Good Reason, Mr. Skibsted will be entitled to receive, subject to his execution and non-revocation of a separation agreement and release of claims in favor of the Company and compliance with certain restrictive covenants, (i) an amount equal to the sum of his Base Salary then in effect plus 100% of his annual Target Bonus, payable in equal installments for a one-year period, (ii) reimbursement of COBRA coverage for up to one year, and (iii) Mr. Skibsted&#8217;s Initial Time-Based Options will continue to vest for a period of one year and his Initial Performance-Based Options, to the extent outstanding and unvested as of the date of such termination, will immediately terminate. All vested stock options held by Mr. Skibsted that are </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">exercisable as of the date of such termination and all Initial Time-Based Options that become exercisable over the one-year period following such termination will remain exercisable until the earlier of one year following such termination and the expiration date of the stock options.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Employment Agreement, in the event of a Change of Control, upon a termination of Mr. Skibsted&#8217;s employment by the Company without Cause or by Executive for Good Reason during the Effective Period, subject to his compliance with certain restrictive covenants, Mr. Skibsted will be entitled to receive: (i) a pro-rated Target Bonus based on the number of days employed during the year of termination, (ii) an amount equal to 1.5 times the sum of his Base Salary then in effect plus 100% of his annual Target Bonus, (iii) reimbursement of COBRA coverage for up to one year and (iv) any equity awards held by Mr. Skibsted subject to time-based vesting conditions will accelerate and become fully vested and the Initial Performance-Based Options, to the extent outstanding and unvested as of the date of such termination, will immediately terminate. All stock options held by Mr. Skibsted that are exercisable as of the date of such termination will remain exercisable until the expiration date of the stock options.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Employment Agreement, Mr. Skibsted also entered into the Company&#8217;s form of Employee Confidentiality, Assignment of Inventions, Non-Interference and Non-Competition Agreement.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Capitalized terms used in herein, but not defined, shall have the meanings given to them in the Employment Agreement. The foregoing summary of the Employment Agreement does not purport to be a complete description of the Employment Agreement and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.789%;"><tr><td style="width:1.0%;"></td><td style="width:8.722%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.376%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:86.502%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Item 8.01</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Other Events.</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 15, 2020, the Company issued a press release announcing the appointment of Mr. Skibsted as Executive Vice President, Chief Financial Officer and Chief Business Officer. Attached hereto as Exhibit 99.1 and incorporated herein by reference, is a copy of the press release.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 8.01, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.789%;"><tr><td style="width:1.0%;"></td><td style="width:8.722%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.376%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:86.502%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Item 9.01</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Financial Statements and Exhibits.</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;Exhibits&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following exhibit is being furnished herewith:</span></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">EXHIBIT&#160;INDEX</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.228%;"><tr><td style="width:1.0%;"></td><td style="width:8.675%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:1.944%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:86.081%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit&#160;No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex-rockwellxxskibstede.htm">Russell Skibsted Employment Agreement, dated September 1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex-rockwellxxskibstede.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex-rockwellxxskibstede.htm">, 2020</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex-rmtix20200915xrsxcf.htm">Press Release, dated September 15, 2020</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SIGNATURE</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:46.847%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.592%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.261%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ROCKWELL MEDICAL,&#160;INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: September 16, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;Russell Ellison</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Russell Ellison</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex-rockwellxxskibstede.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic01f9da2936e4e0eb4306b14fceb2e0b_1"></div><div style="min-height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Execution Copy                                                                                                           Exhibit 10.1   </font></div></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Employment Agreement</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Employment Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is made as of September __, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), by and between Rockwell Medical,&#160;Inc., a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and Russell L. Skibsted (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Executive</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), subject to the terms and conditions defined in this Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Whereas, the Company and Executive desire the Executive be employed by the Company to act as the Company&#8217;s Executive Vice President, Chief Financial Officer and Chief Business Officer (collectively, the &#8220;CFO&#8221;), subject to the terms and conditions set forth in this Agreement and such policies and procedures as the Company may from time to time implement and that are provided to the Executive&#59;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Now, Therefore, in consideration of the covenants contained herein, and for other valuable consideration, the Company and Executive hereby agree as follows&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Certain Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; Certain definitions used herein shall have the meanings set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit&#160;A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> attached hereto.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Executive&#8217;s Duties and Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Duties&#59; Start Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; Executive shall serve as the Company&#8217;s CFO effective on September __, 2020, or such other mutually agreeable date (such date being referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Commencement Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Executive shall report to the President and Chief Executive Officer of the Company (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">CEO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and the Board of Directors (the &#8220;Board&#8221;).  Executive shall have those duties and responsibilities customarily associated with the position of CFO of a public-traded company of the size and nature of the Company, and such other additional business and operational duties and responsibilities consistent with Executive&#8217;s position as may, from time to time, be assigned to Executive by the CEO or the Board.   </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">At-Will Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive&#8217;s employment shall be on an at-will basis, meaning that either party may terminate this employment arrangement at any time and without cause.  The term of this Agreement shall be from the Effective Date through the applicable date of termination (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  On the date of termination of employment, Executive acknowledges that he shall immediately be deemed to have resigned all employment and related job duties and responsibilities with the Company, including, without limitation, any Board position and any positions on any Company committees or boards or any affiliated company.  Executive agrees to sign all reasonable documentation evidencing the foregoing as may be presented to Executive for signature by the Company. </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Confidential Information and Inventions Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; In consideration of the covenants contained herein, Executive has executed and agrees to be bound by the Company&#8217;s form of Employee Confidentiality, Assignment of Inventions, Non-Interference and Non-Competition Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Confidentiality Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), in the form attached to this Agreement as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit&#160;B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; Executive shall comply in all material respects at all times with the terms and conditions of the Confidentiality Agreement and all other reasonable policies of the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:right;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Company governing its confidential and proprietary information.  In the event that Executive breaches any provisions of this Agreement or the Confidentiality Agreement, then, in addition to any other rights which the Company may have, the Company shall be entitled, without the posting of a bond or other security, to seek injunctive relief to enforce the restrictions contained therein.&#160; In the event that an actual proceeding is brought in equity to enforce the provisions of this Agreement or the Confidentiality Agreement, Executive shall not assert as a defense that there is an adequate remedy at law, nor shall the Company be prevented from seeking any other remedies which may be available.</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Devotion of Time to Company&#8217;s Business</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Full-Time Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; During Executive&#8217;s employment with the Company, Executive shall devote substantially all of Executive&#8217;s business time, attention and efforts to the proper performance of Executive&#8217;s duties and obligations hereunder.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">No Other Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; During Executive&#8217;s employment with the Company, Executive shall not, except as otherwise provided herein, directly or indirectly, render any services of a commercial or professional nature to any other person or organization, whether for compensation or otherwise, without the prior written consent of the CEO&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that it shall not be a violation or breach of this Agreement for Executive to (i)&#160;accept speaking or presentation engagements in exchange for honoraria&#59; (ii)&#160;serve on boards of charitable organizations or participate in charitable, educational, religious or civic activities&#59; (iii) serve on the Board of another company (public or private) after completion of one (1) year of continuous employment with the Company upon approval of the CEO and the Board&#59; (iv)&#160;attend to his and his family&#8217;s personal affairs&#59; or (v)&#160;own no more than three percent (3%) of the outstanding equity securities of a corporation whose stock is listed on a national stock exchange, so long as such activities are not adverse to the Company&#8217;s interests and do not materially interfere with the performance of Executive&#8217;s duties hereunder.</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Compensation and Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Base Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; During the Term, the Company shall pay to Executive base annual compensation (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) of $460,000 ($38,333.33 monthly), payable in accordance with the Company&#8217;s regular payroll practices and less all required withholdings benefits as hereinafter set forth in this Section&#160;4.&#160; Executive&#8217;s Base Salary shall be reviewed annually and may be increased based on an assessment of Executive&#8217;s performance, the performance of the Company, inflation, the then prevailing salary scales for comparable positions and other relevant factors&#59; provided, however, that any increase in Base Salary shall be solely within the discretion of the Compensation Committee of the Company&#8217;s Board .  Executive&#8217;s Base Salary may not be subject to reduction from the level set forth above, unless pursuant to a salary reduction program of general application to employment contract executives of the Company, provided that, unless agreed to in writing by Executive, the percentage reduction of Executive&#8217;s Base Salary shall not be greater than the percentage reduction applied to any other employment contract executive of the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Bonuses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:60.69pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Performance-Based Bonus(s)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Following the Commencement Date,   Executive shall be eligible to receive the First Performance-Based Bonus in the aggregate amount of $75,000 in cash, subject to Executive&#8217;s continuous employment by the Company through the six (6)-month anniversary of the Commencement Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">First Bonus Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  In addition, the Executive shall be eligible to receive the Second Performance-Based Bonus in the aggregate amount of $50,000 in cash, subject to Executive&#8217;s continuous employment by the Company through the twelve (12)-month anniversary of the Commencement Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Second Bonus Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The First Performance-Based Bonus shall be paid within five (5) days of the First Bonus Date, and the Second Performance-Based Bonus shall be paid within five (5) days of the Second Bonus Date&#59; provided, that payment shall only be made following such applicable bonus dates subject to (i) the CEO&#8217;s determination that Executive has performed his duties under this Agreement through the applicable bonus date in a satisfactory manner and (ii) approval of each such applicable payment by the Board.  For the avoidance of doubt, the Performance-Based Bonus(s) described in this Section 4(b)(i) shall be payable once and only once. </font></div><div style="text-indent:52.86pt;padding-left:4.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  During the Term, Executive shall be eligible for year-end bonuses, which shall be paid in cash (any such bonus an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Annual Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), in a target amount equal to 60% of Executive&#8217;s Base Salary, as then in effect (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Target Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), as may be awarded pursuant to any annual executive bonus plan and related corporate goals approved solely at the discretion of the Compensation Committee of the Board.&#160; Any such Annual Bonus shall contain such rights and features as are typically afforded to other contract executives of the Company. Executive shall be first eligible to receive an Annual Bonus commencing with the 2021 calendar year, which would be paid in 2022. Executive must be employed by the Company on the date such bonuses are paid. </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Long-Term Incentive Grants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; As of the Commencement Date, the Executive will eligible to participate in the Company&#8217;s Amended and Restated 2018 Long Term Incentive Plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Such awards will be subject in all respects to the terms and conditions of the Plan and the forms of award agreement adopted by the Board for use thereunder.   </font></div><div style="text-indent:60.69pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Initial Option Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  On the Commencement Date, as a material inducement to Executive agreeing to join the Company, Executive shall be awarded an option to purchase up to 750,000 shares of common stock (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Option</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The Option will have an exercise price equal to the closing price of the Company&#8217;s common stock on the Commencement Date and will vest and become exercisable as follows&#58; (1) 200,000 will vest and become exercisable ratably on each of the first three anniversaries of the Commencement Date so that the Option is fully vested and exercisable on the third anniversary of the Commencement Date, subject to the Executive&#8217;s continued service through each applicable vesting date&#59; (2) 75,000 shall vest and become exercisable if the annualized net sales run rate for Triferic (measured over any given fiscal quarter) meets or exceeds $20,000,000 by no later than December 31, 2021 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Net Sales Performance Option</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), provided that, a pro-rata portion of the Net Sales Performance Option shall vest to the extent the net annualized sales run rate (measured quarterly) meets or exceeds $14,500,000 by December 31, 2020&#59; and (3) 75,000 shall vest and become exercisable if the Company commences a Phase II Study for Triferic in a second indication of Triferic by no later </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">than April 17, 2021.  The Options described in this Section 4(c)(i)(2) and 4(c)(i)(3) shall be referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Contingent Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;.  </font></div><div style="text-indent:61.86pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Annual Equity Grants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. During the Term, Executive shall be eligible to receive annual long-term incentive grants consistent with similar practices for the Company&#8217;s senior executives, which may be paid in either cash or equity, or both (any such grants a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Long-Term Incentive Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), as may be awarded solely at the discretion of the Compensation Committee of the Board&#59; provided that the Compensation Committee shall be under no obligation whatsoever to grant such discretionary Long-Term Incentive Grants.&#160; Any Long-Term Incentive Grants issued to Executive shall be governed by the Company&#8217;s then-applicable long-term incentive plan(s) and any long-term incentive grant agreement(s)&#160;under the then applicable long-term incentive plan(s) under which they are issued. </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; During the Term, Executive shall be entitled to participate in all employee benefit plans, programs and arrangements made available generally to the Company&#8217;s senior executives or to its employees on substantially the same basis that such benefits are provided to such senior executives&#59; provided, however, that nothing in this Agreement shall be construed to require the Company to establish or maintain any particular plans, programs or arrangements.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Vacations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; During the Term, Executive shall be entitled to 20 days paid-time off (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">PTO</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) days, to be earned ratably throughout the year starting on the Commencement Date.&#160; PTO days may be only carried from one year to the next in accordance with the Company PTO policy, provided that the Executive shall not be entitled to carry forward into the following year a balance of more than 10 PTO days.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Reimbursement of Business Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive is authorized to incur reasonable expenses in carrying out Executive&#8217;s duties and responsibilities under this Agreement and the Company shall reimburse Executive for all reasonable expenses, in accordance with and subject to the applicable policies and procedures of the Company.  In addition, the Company shall promptly reimburse the Executive for all reasonable legal fees incurred by Executive in connection with the review, negotiation, drafting and execution of this Agreement, up to a cap of $5,000.</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Termination of Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Termination by the Company for Cause or Termination by Executive without Good Reason, Death or Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i) In the event of a termination of Executive&#8217;s employment by the Company for Cause, a termination by Executive without Good Reason, or in the event this Agreement terminates by reason of the death or Disability of Executive, Executive shall be entitled to any unpaid compensation accrued through the last day of Executive&#8217;s employment, a lump sum payment in respect of all accrued but unused PTO days at Executive&#8217;s Base Salary in effect on the date such PTO was earned, and payment of any other amounts owing to Executive but not yet paid, less any amounts owed by Executive to the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Accrued Amounts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).&#160; Executive </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shall not be entitled to receive any other compensation or benefits from the Company whatsoever (except as provided below and as and to the extent the continuation of certain benefits is required by law).</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">In the case of a termination due to death or Disability, notwithstanding any provision to the contrary in any stock option, restricted stock or other equity award agreement between the Company and Executive, (x) all shares underlying Executive&#8217;s time-based outstanding equity awards, including all options that are time-based awards (as opposed to performance-based) to acquire Company stock held by Executive shall accelerate and become fully vested upon the Date of Termination and (y) the Contingent Options, to the extent outstanding as of the date of such termination, shall accelerate, if at all, in accordance with the terms of the stock option award agreement evidencing such Contingent Options and all such exercisable time-based options and Contingent Options (if any), shall thereupon remain fully exercisable until the earlier of (i) one (1) year from date of termination due to death or Disability or (ii) the expiration of their stated terms.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Termination by the Company without Cause or by Executive for Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; If (x)&#160;Executive&#8217;s employment is terminated by the Company other than for Cause, death or Disability (i.e., without Cause) or (y)&#160;Executive terminates employment with Good Reason, then Executive will receive the Accrued Amounts and, on the condition that the Executive signs a separation agreement containing a  plenary release of claims in  the form attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereto (subject to any changes required by applicable law), which such plenary release becomes final, binding and irrevocable within 30 days after the Date of Termination (or such longer period of time as required by applicable law), the Executive shall also be entitled to receive the following from the Company&#58;</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">(x) An amount equal to the sum of (A) the Executive&#8217;s annualized Base Salary then in effect&#59; and (B) 100% of the annual Target Bonus then in effect (both determined without regard to any reduction in such Base Salary constituting Good Reason), payable in equal installments in accordance with the Company&#8217;s regular payroll schedule, from the Date of Termination to the date that is 12 months after the Date of Termination (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Severance Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; provided, however, that each installment payable before the plenary release becomes final, binding and irrevocable shall not be paid to the Executive until such plenary release becomes final, binding and irrevocable (at which time all such amounts that would have been paid but for the delay described in this clause (i)&#160;shall be paid)&#59; provided further, however, that if the time period for the release to be executed and become irrevocable spans two calendar years, the installment payments due once the plenary release becomes final, binding and irrevocable shall be paid no earlier than January 1 of the later calendar year&#59; </font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">During the Severance Period, if Executive elects to continue Company medical benefits through the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Company shall reimburse the Executive for the out-of-pocket cost of continuing medical benefits, on the same terms and conditions as such benefits are provided to active employees of the Company, for up to 12 months.&#160;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">Subject to the plenary release becoming final, binding and irrevocable, notwithstanding any provision to the contrary in any stock option or restricted stock or other equity award agreement between the Company and the Executive, (x) the time-based equity awards set forth in Section&#160;4(c)(i)&#160;shall continue to vest over the Severance Period.  The Contingent Options, to the extent outstanding and unvested as of the date of such termination, shall immediately terminate.  All vested stock options to acquire Company stock and all other similar vested equity awards held by the Executive as of the Date of Termination, including any vested Contingent Options, if any, and the time-based stock options that continue to vest over the Severance Period, shall continue to be exercisable for a period of one year from the Date of Termination, or, if earlier, until the ultimate expiration date of such awards&#59; and </font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">Notwithstanding the foregoing, if Executive engages in a material breach of any provision of this Agreement or the Confidentiality Agreement during the Severance Period (or the period applicable to such obligation, if shorter or longer), and such breach is not cured within five business days after receipt from the Company of notice thereof, then the Company&#8217;s continuing obligations under this Section&#160;5(b)&#160;shall cease as of the date of the breach and the Executive shall be entitled to no further payments or benefits hereunder.</font></div><div style="text-indent:29.67pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination in connection with a Change of Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; In the event of a Change of Control, if Executive&#8217;s employment is terminated by the Company other than for Cause or by Executive for Good Reason during the Effective Period, then Executive shall be entitled to receive the following from the Company&#58; </font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">The Accrued Amounts&#59;</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">f.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt;">Within 10 days after the Date of Termination, a lump sum cash payment equal to the Target Bonus, multiplied by the fraction obtained by dividing the number of days Executive was employed during the calendar year in which the Date of Termination occurs by 365&#59;</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">g.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">Within 10 days after the Date of Termination, a lump sum cash payment in an amount equal to 1.5 times the sum of (A)&#160;Executive&#8217;s annual Base Salary then in effect, plus (B) 100% of Executive&#8217;s Target Bonus (in each case, determined without regard to any reduction in such Base Salary constituting Good Reason)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if Executive&#8217;s employment is terminated prior to the consummation of a Change of Control but under circumstances that would cause the Change of Control Date to precede the date that the Change of Control is consummated, such amount will be paid in equal installments in accordance with the Company&#8217;s regular payroll schedule over the Benefit Period (defined below), subject to all remaining installments being paid in a lump sum on the date on which the Change of Control is consummated&#59;</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">h.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">If Executive elects to continue Company medical benefits under COBRA, for a period of 12 months following the Date of Termination (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Benefit Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Company shall reimburse the Executive for the out-of-pocket cost of continuing medical benefits for such period on the same terms and conditions as such benefits are provided to active employees of the Company.&#160;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;">Notwithstanding any provision to the contrary in any stock option, restricted stock or other equity award agreement between the Company and Executive, (x) all shares underlying Executive&#8217;s time-based outstanding equity awards, including all options that are time-based awards (as opposed to performance-based) to acquire Company stock held by Executive shall accelerate and become fully vested upon the Date of Termination and all restrictions thereon shall be lifted, (y) the Contingent Options, to the extent outstanding and unvested as of the date of such termination, shall immediately terminate, and (z) all exercisable time-based stock options and Contingent Options (if any) shall continue to be exercisable for the remainder of their stated terms&#59; and</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">j.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;">Notwithstanding the foregoing, if Executive engages in a material breach of any provision of this Agreement or Executive&#8217;s Confidentiality Agreement during the Benefits Period, and such breach is not cured within five business days after receipt from the Company of notice thereof, then the Company&#8217;s continuing obligations under this Section&#160;5(c) shall cease as of the date of the breach and the Executive shall be entitled to no further payments or benefits hereunder.</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:26.34pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.Any termination of Executive&#8217;s employment by the Company for Cause, or by Executive for Good Reason shall be communicated by a Notice of Termination to the other party hereto given in accordance with Section&#160;10.&#160; For purposes of this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Notice of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a written notice which&#58;&#160;(i)&#160;is given at least 10 days prior to the Date of Termination (at least 30 days in the case of Notice of Termination given by Executive for Good Reason, following the notice and cure period set forth below in the definition of Good Reason)&#59; (ii)&#160;indicates the specific termination provision in this Agreement relied upon&#59; (iii)&#160;to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#8217;s employment under the provision so indicated&#59; and (iv)&#160;specifies the employment termination date. </font></div><div style="text-indent:23.01pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iii.A termination of employment of Executive will not be deemed to be for Good Reason unless Executive gives the Notice of Termination provided for herein within 30 days after Executive has actual knowledge of the act or omission of the Company constituting such Good Reason and Executive gives the Company a 30-day cure period to rectify or correct the condition or event that constitutes Good Reason and Executive delivers final Notice of Termination within 30 days of the date that Company&#8217;s failure to cure deadline has expired, which final Notice of Termination must specify a Date of Termination of no later than 30 days after the final Notice of Termination is provided.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;"> Mitigation of Damages</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; Executive will not be required to mitigate damages or the amount of any payment or benefit provided for under this Agreement by seeking other employment or otherwise.&#160; Except as otherwise provided in Sections 5(b)(ii)&#160;and 5(c)(iv), the amount of any payment or benefit provided for under this Agreement will not be reduced by any compensation or benefits earned by Executive as the result of self-employment or employment by another employer or otherwise.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Excess Parachute Excise Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:23.67pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iv.Anything in this Agreement to the contrary notwithstanding, in the event it shall be determined that any payment, award, benefit or distribution (including any acceleration) by the Company or any entity which effectuates a transaction described in Section 280G(b)(2)(A)(i)&#160;of the Code to or for the benefit of Executive (whether pursuant to the terms of this Agreement or otherwise, but determined without regard to any additional payments required under this Section&#160;8) (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) would be subject to the excise tax imposed by Section&#160;4999 of the Code or any interest or penalties are incurred with respect to such excise tax by Executive (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Excise Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Company will automatically reduce such Payments to the extent, but only to the extent, necessary so that no portion of the remaining Payments will be subject to the Excise Tax, unless the amount of such Payments that the Executive would retain after payment of the Excise Tax and all applicable Federal, state and local income taxes without such reduction would exceed the amount of such Payments that the Executive would retain after payment of all applicable Federal, state and local taxes after applying such reduction.&#160; Unless otherwise elected by the Executive to the extent permitted under Code Section&#160;409A, the Company shall reduce or eliminate the Payments by first reducing or eliminating any cash severance benefits (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating any accelerated vesting of stock options or similar awards, then by reducing or eliminating any accelerated vesting of restricted stock or similar awards, then by reducing or eliminating any other remaining Payments&#59; provided, that no such reduction or elimination shall apply to any non-qualified deferred compensation amounts (within the meaning of Section&#160;409A of the Code) to the extent such reduction or elimination would accelerate or defer the timing of such payment in manner that does not comply with Section&#160;409A of the Code.</font></div><div style="text-indent:27pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">v.All determinations required to be made under this Section&#160;8, including the assumptions to be utilized in arriving at such determination, shall be made by the Company&#8217;s independent auditors or such other certified public accounting firm reasonably acceptable to Executive as may be designated by the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Accounting Firm</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) which shall provide detailed supporting calculations both to the Company and Executive within 15 business days of the receipt of notice from Executive that there has been a Payment, or such earlier time as is requested by the Company.&#160; All fees and expenses of the Accounting Firm shall be borne solely by the Company.&#160; Any determination by the Accounting Firm shall be binding upon the Company and Executive.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Legal Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; Each party shall be responsible for its own legal fees and expenses in connection with any claim or dispute relating to this Agreement. </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered by hand or mailed within the continental United States by first class certified mail, return receipt requested, postage prepaid, addressed as follows&#58;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">if to the Company&#58;</font></div><div style="padding-left:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Rockwell Medical, Inc.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">411 Hackensack Ave. Suite 501</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Hackensack, New Jersey 07601 </font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attn&#58; President and Chief Executive Officer</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">if to Executive&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The address on file with the records of the Company</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Addresses may be changed by written notice sent to the other party at the last recorded address of that party.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; The Company shall be entitled to withhold from payments due hereunder any required federal, state or local withholding or other taxes.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; This Agreement, together with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit&#160;A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and the Confidentiality Agreement, contains the entire agreement between the parties with respect to the subject matter hereof and supersedes all other prior agreements, written or oral, with respect thereto.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:23.67pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">vi.If the parties are unable to resolve any dispute or claim relating directly or indirectly to this Agreement or any dispute or claim between Executive and the Company or its officers, directors, agents, or employees (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Dispute</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), then either party may require the matter to be settled by final and binding arbitration by sending written notice of such election to the other party clearly marked &#8216;Arbitration Demand.&#8217;&#160; Such Dispute shall be arbitrated in accordance with the terms and conditions of this Section&#160;13.&#160; Notwithstanding the foregoing, either party may apply to a court of competent jurisdiction for a temporary restraining order, a preliminary injunction, or other equitable relief to preserve the status quo or prevent irreparable harm.</font></div><div style="text-indent:20.34pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">vii.The Dispute shall be resolved by a single arbitrator in an arbitration administered by the American Arbitration Association in accordance with its Employment Arbitration Rules&#160;and judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.&#160; The decision of the arbitrator shall be final and binding on the parties, and specific performance giving effect to the decision of the arbitrator may be ordered by any court of competent jurisdiction.</font></div><div style="text-indent:17.01pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">viii.Nothing contained herein shall operate to prevent either party from asserting counterclaim(s)&#160;in any arbitration commenced in accordance with this Agreement, and any such party need not comply with the procedural provisions of this Section&#160;13 in order to assert such counterclaim(s).</font></div><div style="text-indent:23.67pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ix.The arbitration shall be filed with the office of the American Arbitration Association (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">AAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) located in New York, New York or such other AAA office as the parties may agree upon (without any obligation to so agree).&#160; The arbitration shall be conducted pursuant to the Employment Arbitration Rules&#160;of AAA as in effect at the time of the arbitration hearing, such </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">arbitration to be completed in a 60-day period.&#160; In addition, the following rules&#160;and procedures shall apply to the arbitration&#58;</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">k.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The arbitrator shall have the sole authority to decide whether or not any Dispute between the parties is arbitrable and whether the party presenting the issues to be arbitrated has satisfied the conditions precedent to such party&#8217;s right to commence arbitration as required by this Section&#160;13.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">l.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;">The decision of the arbitrator, which shall be in writing and state the findings, the facts and conclusions of law upon which the decision is based, shall be final and binding upon the parties, who shall forthwith comply after receipt thereof.&#160; Judgment upon the award rendered by the arbitrator may be entered by any competent court.&#160; Each party submits itself to the jurisdiction of any such court, but only for the entry and enforcement to judgment with respect to the decision of the arbitrator hereunder.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">m.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.67pt;">The arbitrator shall have the power to grant all legal and equitable remedies (including, without limitation, specific performance) and award compensatory and punitive damages if authorized by applicable law.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">n.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The parties shall bear their own costs in preparing for and participating in the resolution of any Dispute pursuant to this Section&#160;13, and the costs of the arbitrator(s)&#160;shall be equally divided between the parties.</font></div><div style="text-indent:72pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">o.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">Except as provided in the last sentence of Section 13(a), the provisions of this Section&#160;13 shall be a complete defense to any suit, action or proceeding instituted in any federal, state or local court or before any administrative tribunal with respect to any Dispute arising in connection with this Agreement.&#160; Any party commencing a lawsuit in violation of this Section&#160;13 shall pay the costs of the other party, including, without limitation, reasonable attorney&#8217;s fees and defense costs.</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:27pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">x.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of Delaware without regard to the application of choice-of-law rules.</font></div><div style="text-indent:23.67pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xi.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by the parties hereto.</font></div><div style="text-indent:20.34pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; If one or more provisions of this Agreement are held to be invalid or unenforceable under applicable law, such provisions shall be construed, if possible, so as to be enforceable under applicable law, or such provisions shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:17.01pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xiii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Binding Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; This Agreement shall be binding upon and inure to the benefit of the beneficiaries, heirs and representatives of Executive (including the Beneficiary) and the successors and assigns of the Company.&#160; The Company shall require any successor (whether direct or indirect, by purchase, merger, reorganization, consolidation, acquisition of property or stock, liquidation, or otherwise) to all or substantially all of its assets, by agreement in form and substance satisfactory to Executive, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform this Agreement if no such succession had taken place.&#160; Regardless whether such agreement is executed, this Agreement shall be binding upon any successor of the Company in accordance with the operation of law and such successor shall be deemed the Company for purposes of this Agreement.</font></div><div style="text-indent:17.67pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xiv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Successors and Assigns</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; Except as provided in Section&#160;14(d)&#160;in the case of the Company, or to the Beneficiary in the case of the death of Executive, this Agreement is not assignable by any party and no payment to be made hereunder shall be subject to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or other charge.</font></div><div style="text-indent:21pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Remedies Cumulative&#59; No Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; No remedy conferred upon either party by this Agreement is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given hereunder or now or hereafter existing at law or in equity.&#160; No delay or omission by either party in exercising any right, remedy or power hereunder or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in such party&#8217;s sole discretion.</font></div><div style="text-indent:17.67pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xvi.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Survivorship</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; Notwithstanding anything in this Agreement to the contrary, all terms and provisions of this Agreement that by their nature extend beyond the termination of the Term shall survive such termination.</font></div><div style="text-indent:14.34pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xvii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute one document.&#160; Signatures to this Agreement may be delivered by any electronic means.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Section&#160;409A of the Code</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from, Section&#160;409A of the Code and, accordingly, to the maximum extent permitted, this Agreement shall be construed and interpreted in accordance with such intent.&#160; Executive&#8217;s termination of employment (or words to similar effect) shall not be deemed to have occurred for purposes of this Agreement unless such termination of employment constitutes a &#8220;separation from service&#8221; within the meaning of Code Section&#160;409A and the regulations and other guidance promulgated thereunder.</font></div><div style="text-indent:11.01pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xviii.Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed on the date of Executive&#8217;s termination to be a &#8220;specified employee&#8221; within the meaning of that term under Code Section&#160;409A(a)(2)(B)&#160;and using the identification methodology selected by the Company from time to time, or if none, the default methodology set forth in Code Section&#160;409A, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">then with regard to any payment or the providing of any benefit that constitutes &#8220;non-qualified deferred compensation&#8221; pursuant to Code Section&#160;409A and the regulations issued thereunder and not exempt from Code Section 409A as a short-term deferral or otherwise that is payable due to Executive&#8217;s separation from service, to the extent required to be delayed in compliance with Code Section&#160;409A(a)(2)(B), such payment or benefit shall not be made or provided to Executive prior to the earlier of (i)&#160;the expiration of the six (6)&#160;month period measured from the date of Executive&#8217;s separation from service, and (ii)&#160;the date of Executive&#8217;s death.&#160; On the first day of the seventh month following the date of Executive&#8217;s separation from service or, if earlier, on the date of Executive&#8217;s death, all payments delayed pursuant to this Section&#160;15(a)&#160;shall be paid or reimbursed to Executive in a lump sum, and any remaining payments and benefits due to Executive under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. </font></div><div style="text-indent:17.67pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xix.To the extent any reimbursement of costs and expenses provided for under this Agreement constitutes taxable income to Executive for Federal income tax purposes, such reimbursements shall be made no later than December&#160;31 of the calendar year next following the calendar year in which the expenses to be reimbursed are incurred.&#160; With regard to any provision herein that provides for reimbursement of expenses or in-kind benefits, except as permitted by Code Section&#160;409A, (i)&#160;the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit, (ii)&#160;the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.&#160; Any tax gross-ups provided for under this Agreement shall in no event be paid to Executive later than the December&#160;31 of the calendar year following the calendar year in which the taxes subject to gross-up are incurred or paid by Executive.</font></div><div style="text-indent:21pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xx.If any amount under this Agreement is to be paid in two or more installments, for purposes of Code Section&#160;409A each installment shall be treated as a separate payment.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Indemnification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  During Executive&#8217;s employment, the Company shall maintain directors&#8217; and officers&#8217; liability insurance that is applicable to Executive. The Company shall indemnify Executive and hold Executive harmless from and against any claim, loss or cause of action arising from or out of Executive&#8217;s performance prior to or after the Commencement Date (and within the scope of his employment) as an officer, director or employee of the Company or any of its subsidiaries or other affiliates or predecessors or in any other capacity, including any fiduciary capacity, in which Executive serves at the Company&#8217;s request, in each case to the maximum extent permitted by applicable corporate law and, to the extent more favorable, to the maximum extent permitted under the Company&#8217;s Certificate of Incorporation and By-Laws.&#160; On the Commencement Date, the Company shall execute and deliver to Executive an Indemnification Agreement, in the form adopted by the Board, pursuant to which the Company agrees to indemnify Executive and advance defense costs and expenses. The rights under this Section&#160;16 shall in all cases be on terms no less favorable to Executive than to other senior executives of the Company and shall survive the termination of employment until the expiration of the applicable statute of limitations.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">17.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Executive Acknowledgement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; Executive hereby acknowledges that Executive has read and understands the provisions of this Agreement, that Executive has been given the opportunity for Executive&#8217;s legal counsel to review this Agreement, that the provisions of this Agreement are reasonable and that Executive has received a copy of this Agreement.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;remainder of page intentionally left blank&#93;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the parties hereto have caused this Employment Agreement to be executed as of the Effective Date.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROCKWELL MEDICAL,&#160;INC.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Russell H. Ellison, MD</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; President &#38; CEO</font></div><div style="margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Executive</font></div><div style="margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Russell L. Skibsted</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT&#160;A</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Beneficiary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any individual, trust or other entity named by Executive to receive the payments and benefits payable hereunder in the event of the death of Executive.&#160; Executive may designate a Beneficiary to receive such payments and benefits by completing a form provided by the Company and delivering it to the General Counsel or Secretary of the Company.&#160; Executive may change his designated Beneficiary at any time (without the consent of any prior Beneficiary) by completing and delivering to the Company a new beneficiary designation form.&#160; If a Beneficiary has not been designated by Executive, or if no designated Beneficiary survives Executive, then the payment and benefits provided under this Agreement, if any, will be paid to Executive&#8217;s estate, which shall be deemed to be Executive&#8217;s Beneficiary.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means&#58;&#160;(i) Executive&#8217;s material breach of this Agreement or any other material policy of the Company, in each instance only after a written demand to cure such breach is delivered to Executive setting forth in reasonable detail the circumstances of such breach and Executive fails to cure such breach (if it reasonably can be cured) within the thirty (30) day period following his receipt of such written notice&#59; (ii) Executive&#8217;s continued willful neglect of Executive&#8217;s duties with the Company or willful failure to comply with an express lawful written directive relating to Executive&#8217;s duties (other than as a result of Executive&#8217;s incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to Executive, which specifically identifies the manner in which the Company believes that Executive has neglected his duties or failed to comply with a lawful directive and Executive fails to comply with such written demand within the thirty (30) day period following its receipt&#59; (iii) any material act of dishonesty, or any act of misappropriation, embezzlement, fraud or similar conduct involving the Company or any of its affiliates&#59; (iv) the conviction of or the plea of nolo contendere or the equivalent by Executive of a felony or other crime involving moral turpitude&#59; or (v) Executive&#8217;s engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company.  No act or failure to act by Executive shall be considered &#8220;willful&#8221; unless it is done or omitted to be done by Executive in bad faith and without reasonable belief that he was acting in the best interests of the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Change of Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a &#8220;Change in Control&#8221; as defined in the Plan. </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Change of Control Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any date after the date hereof on which a Change of Control occurs&#59; provided, however, that if a Change of Control occurs and if Executive&#8217;s employment with the Company is terminated or an event constituting Good Reason (as defined below) occurs prior to the Change of Control, and if it is reasonably demonstrated by Executive that such termination or event&#58; (i)&#160;was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control, or (ii)&#160;otherwise arose in connection with or in anticipation of the Change of Control then, for all purposes of this Agreement, the Change of Control Date shall mean the date immediately prior to the date of such termination or event.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Code</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Date of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the date specified in a Notice of Termination pursuant to Section&#160;6 hereof, or Executive&#8217;s last date as an active employee of the Company before a termination of employment due to death, Disability or other reason, as the case may be.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a mental or physical condition that renders Executive substantially incapable of performing his duties and obligations under this Agreement, after taking into account provisions for reasonable accommodation, as determined by a medical doctor (such doctor to be mutually determined in good faith by the parties) for three or more consecutive months or for a total of six months during any 12 consecutive months&#59; provided, that during such period the Company shall give Executive at least 30 days&#8217; written notice that it considers the time period for disability to be running.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Effective Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the period beginning on the Change of Control Date and ending 18 months after the date of the related Change of Control.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, subject to the notice and cure provisions set forth in Section 6(b), and unless Executive has consented in writing thereto, the occurrence of any of the following&#58;&#160;(i)&#160;the assignment to Executive of any duties materially inconsistent with Executive&#8217;s position under this Agreement, including any material change in status, title, authority, reporting, duties or responsibilities, or other action which results in a material diminution in Executive&#8217;s authorities, duties, responsibilities or reporting&#59; (ii)&#160;a reduction in Executive&#8217;s Base Salary by the Company of more than 5%, unless such reduction is made proportionately in connection with broader salary reductions among all of the Company&#8217;s executive officers&#59; (iii)&#160;the relocation of Executive&#8217;s principal work location of more than 30 miles&#59; or (iv)&#160;the Company&#8217;s material breach of this Agreement or any other material written agreement between the Company and Executive. </font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT&#160;B</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EMPLOYEE CONFIDENTIALITY, ASSIGNMENT OF INVENTIONS, NON-INTERFERENCE AND NON-COMPETITION AGREEMENT</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The following is an agreement (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is made as of September __, 2020 between Rockwell Medical,&#160;Inc., a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and any successor in interest, and me, Russell L. Skibsted, and this Agreement is a material part of the consideration for my Employment Agreement with the Company&#58;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Job Title and Responsibility</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I understand that my job title with the Company will be Executive Vice President, Chief Financial Officer and Chief Business Officer.&#160; My job duties and responsibilities will be those set forth in my Employment Agreement with the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Consideration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I understand that the consideration to me for entering into this Agreement is my Employment Agreement with the Company, and I agree that this consideration is fully adequate to support this Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Proprietary Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I acknowledge that the Company is engaged in a continuous program of research, development and production.&#160; I also acknowledge that the Company possesses or has rights to secret, private, confidential information and processes (including processes and information developed by me during my employment by the Company) which are valuable, special and unique assets of the Company and which have commercial value in the Company&#8217;s business (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Proprietary Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).&#160; Proprietary Information includes, but is not limited to, information and details regarding the Company&#8217;s business, trade or business secrets, inventions, intellectual property, systems, policies, records, reports, manuals, documentation, models, data and data bases, products, processes, operating systems, manufacturing techniques, research and development techniques and processes, devices, methods, formulas, compositions, compounds, projects, developments, plans, research, financial data, personnel data, internal business information, strategic and staffing plans and practices, business, marketing, promotional or sales plans, practices or programs, training practices and programs, costs, rates and pricing structures and business methods, computer programs and software, customer and supplier identities, information and lists, confidential information regarding customers and suppliers, and contacts at or knowledge of Company suppliers and customers or of prospective or potential customers and suppliers of the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Obligation of Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I understand and agree that my employment creates a relationship of confidence and trust between the Company and me with respect to (i)&#160;all Proprietary Information, and (ii)&#160;the confidential information of others with which the Company has a business relationship.&#160; At all times, both during my employment by the Company and after the termination of my employment (whether voluntary or involuntary),&#160;I will keep in confidence and trust all such information, and I will not use, reveal, communicate, or disclose any such Proprietary Information or confidential information to anyone or any entity, without the written consent of the Company, unless I am ordered to make disclosure by a court of competent jurisdiction.  Notwithstanding any other provision in this Agreement or any other agreement, if I make a confidential disclosure of a Company trade secret to a government agency, government </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">official or an attorney for the purpose of reporting or investigating a suspected violation of law, or in a court filing under seal, I will not be held liable under this Agreement or any other agreement, or under any federal or state trade secret law for such a disclosure.  Moreover, nothing in this Agreement or any other agreement shall prevent me from making a confidential disclosure of any other Proprietary Information to a government official, to an attorney as necessary to obtain legal advice or in a court filing under seal or otherwise as required by law.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  By signing this Agreement, I agree to waive my right to recover individual relief based on any claims asserted in such a complaint or charge&#59; provided, however, that nothing in this Agreement limits my right to receive an award for information I provide to any government agencies that are authorized to provide monetary or other awards to eligible individuals who come forward with information that leads to an agency enforcement action.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ownership, Disclosure and Assignment of Proprietary Information and Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; In addition,&#160;I hereby agree as follows&#58;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(a)&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ownership and Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; All Proprietary Information is, and shall be, the sole and exclusive property of the Company and its successors and assigns, and the Company and its successors and assigns shall be the sole and exclusive owner of all Proprietary Information, including, but not limited to, trade secrets, inventions, patents, trademarks, copyrights, and all other rights in connection with such Proprietary Information.&#160; I agree that I have no rights in Proprietary Information.&#160; I hereby assign, and shall assign, to the Company and its successors and assigns any and all rights, title and interest I may have or acquire in Proprietary Information.&#160; Any copyrightable work prepared in whole or in part by me in the course of my employment shall be deemed &#8220;a work made for hire&#8221; under applicable copyright laws, and the Company and its successors and assigns shall own all of the rights in any copyright.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(b)&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Return of Materials and Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; All documents, records, apparatus, equipment, databases, data and information, whether stored in physical form or by electronic means, and all electronic, computer, intellectual, and physical property (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Materials and Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), whether or not pertaining to Proprietary Information, furnished to me by the Company or produced by me or others in connection with employment, shall be and remain the sole and exclusive property of the Company.&#160; I shall return to the Company all Materials and Property as and when requested by the Company.&#160; Even if the Company does not so request,&#160;I shall return all Materials and Property upon termination of employment by me or by the Company for any reason, and I will not take with me any Materials and Property, or any reproduction thereof, upon such termination.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(c)&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; During the term of my employment and for one (1)&#160;year thereafter,&#160;I will promptly disclose to the Company, or any persons designated by it, all improvements, inventions, intellectual property, works of authorship, formulas, ideas, processes, techniques, discoveries, developments, designs, devices, innovations, know-how and data, and creative works in which copyright and&#47;or unregistered design rights will subsist in various media (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), whether or not such Inventions are patentable, which I make or conceive, contribute to, reduce to practice, or learn, either alone or jointly with others, during the term of my employment.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(d)&#160;&#160;&#160;&#160; Ownership of Inventions.&#160; I agree and acknowledge that all Inventions which I make, conceive, develop, or reduce to practice (in whole or in part, either alone or jointly with others) at any time during my employment by the Company, and (i)&#160;which were created using the equipment, supplies, facilities or trade secret information of the Company&#59; or (ii)&#160;which were developed during the hours for which I was compensated by the Company&#59; or (iii)&#160;which relate, at the time of conception, creation, development or reduction to practice, to the business of the Company or to its actual or demonstrably anticipated research and development&#59; or (iv)&#160;which result from any work performed by me for the Company, shall be the sole and exclusive property of the Company and its successors and assigns (and to the fullest extent permitted by law shall be deemed works made for hire), and the Company and its successors and assigns shall be the sole and exclusive owner of all Inventions, patents, copyrights and all other rights in connection therewith.&#160; I hereby assign to the Company any and all rights I may have or acquire in such Inventions.&#160; I agree that any such Invention required to be disclosed under paragraph (c), above, within one (1)&#160;year after the termination of my employment shall be presumed to have been conceived or made during my employment with the Company and will be assigned to the Company unless and until I prove and establish to the contrary.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(e)&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Assistance and Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; With respect to Inventions described in paragraph (d), above,&#160;I will assist the Company in every proper way (but at the Company&#8217;s expense) to obtain, and from time to time enforce, patents, copyrights or other rights on these Inventions in any and all countries, and will execute all documents reasonably necessary or appropriate for this purpose.&#160; This obligation shall survive the termination of my employment.&#160; In the event that the Company is unable for any reason whatsoever to secure my signature to any document reasonably necessary or appropriate for any of the foregoing purposes (including renewals, extensions, continuations, divisions or continuations in part),&#160;I hereby irrevocably designate and appoint the Company, and its duly authorized officers and agents, as my agents and attorneys-in-fact to act for and in my behalf and instead of me, but only for the purpose of executing and filing any such document and doing all other lawfully permitted acts to accomplish the foregoing purposes with the same legal force and effect as if executed by me.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(f)&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exempt Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I understand that this Agreement does not require assignment of an Invention for which no equipment, supplies, facilities, resources, or trade secret information of the Company was used and which was developed entirely by me on my own time, unless the invention relates (i)&#160;directly to the business of the Company or (ii)&#160;to the Company&#8217;s actual or demonstrably anticipated research or development.&#160; However,&#160;I will disclose to the Company any Inventions I claim are exempt, as required by paragraph (c)&#160;above, in order to permit the Company to determine such issues as may arise.&#160; Such disclosure shall be received in confidence by the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;6.&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Prior Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; As a matter of record, I attach hereto as Exhibit&#160;I a complete list of all inventions or improvements relevant to the subject matter of my employment by the Company which have been made or conceived or first reduced to practice by me, alone or jointly with others, prior to my employment with the Company, that I desire to remove from the operation of this Agreement, and I covenant that such list is complete.&#160; If no such list is attached </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">to this Agreement,&#160;I represent that I have no such inventions and improvements at the time of my signing this Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;7.&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Business Activities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; So that the Company may be aware of the extent of any other demands upon my time and attention,&#160;I will disclose to the Company (such disclosure to be held in confidence by the Company) the nature and scope of any other business activity in which I am or become engaged during the term of my employment.&#160; During the term of my employment,&#160;I will not engage in any business activity or employment which is in competition with, or is related to, the Company&#8217;s business or its actual or demonstrably anticipated research and development, or that will affect in any manner my ability to perform fully all of my duties and responsibilities for the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Non-Interference and Non-Solicitation of Employees, Customers and Others</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;During my employment with the Company and for twelve (12) months after the termination of my employment (whether the termination is by me or the Company, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;),&#160;I will not, and will not attempt to directly or indirectly do any one or more of the following&#58;&#160; (i)&#160;induce, encourage or solicit any employee, consultant, or independent contractor of the Company to leave the Company for any reason, unless specifically requested to take such action in writing by the Company&#59; or (ii)&#160;employ, retain, or engage any employee, consultant, or independent contractor of the Company.&#160; For purposes of this Section&#160;8(a), the terms &#8220;employee&#8221;, &#8220;consultant&#8221; and &#8220;independent contractor&#8221; shall include those who served in such capacities within six (6) months preceding the date of the termination of my employment&#59; provided, that nothing herein shall prevent me from engaging in discussions regarding employment, or employing, any such employee, consultant or independent contractor if such discussions shall be held as a result of, or any employment shall be the result of, the response by any such person to a written employment advertisement placed in a publication of general circulation, general solicitation conducted by executive search firms, employment agencies or other general employment services, not directed specifically at any such employee, consultant or independent contractor.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;During the Restricted Period,&#160;I will not, and will not attempt to, directly or indirectly, solicit, divert, disrupt, interfere with or take away any Company customer, supplier, agent, vendor, distributor, representative, or other contracting party with the Company that had such a relationship with the Company during my employment with the Company to a business that is a Competitor of the Company.&#160; For purposes of this Agreement, the term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Competitor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall include any company or other entity engaged in developing or commercializing any one or more of the following&#58;&#160;(i)&#160;drug products, drug therapies and concentrates&#47;dialysates that target end-stage renal disease and chronic kidney disease for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis or (ii)&#160;any product or process developed and commercialized, or under development in whole or in part, by the Company during my employment.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(c)&#160;During the Restricted Period,&#160;I will not, and will not attempt to, directly or indirectly induce any customer, supplier, agent, vendor, distributor, representative, or other contracting party with the Company that had such a relationship with the Company during my </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">employment with the Company, to reduce its patronage of the Company or to terminate any written or oral agreement or understanding, or any other business relationship with the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;9.&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Non-Competition During and After Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; During the Restricted Period,&#160;I will not directly or indirectly, without the prior written consent of the Company, maintain a relationship with a Competitor including as an employee, employer, consultant, agent, lender, investor, principal, partner, stockholder, corporate officer, director, or in any other individual or representative capacity&#59; provided that, nothing in this Agreement shall prohibit me from being a passive owner of not more than three percent (3%) of the outstanding equity of any entity that itself or through its affiliates in engaged in various businesses including a business that would be considered a Competitor as long as I have no involvement with the competitive business.   I understand and agree that the restrictions in this paragraph are necessary and reasonable to protect the legitimate business interests of the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;10.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Obligations to Former Employers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I represent that my execution of this Agreement, my employment with the Company, and my performance of my duties and proposed duties to the Company will not violate any obligations or agreements I have, or may have, with any former employer or any other third party, including any obligations and agreements requiring me not to compete or to keep confidential any proprietary or confidential information.&#160; I have not entered into, and I will not enter into, any agreement which conflicts with this Agreement or that would, if performed by me, cause me to breach this Agreement.&#160; I further represent that I have no knowledge of any pending or threatened litigation to which the Company may become a party by virtue of my association with the Company.&#160; I further agree to immediately inform the Company of any such pending or threatened litigation should it come to my attention during the course of my employment.&#160; I also represent that I have provided to the Company for its inspection before I signed this Agreement all confidentiality, non-compete, non-solicitation, and all other employment-related agreements and obligations to which I am party to which I am bound.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential Information of, and Agreements with, Former Employers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; In the course of performing my duties to the Company,&#160;I will not utilize any trade secrets, proprietary or confidential information of or regarding any former employer or business affiliate in violation of any duty not to disclose or use such information, nor violate any written or oral, express or implied agreement with any former employer or other third party.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;12.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">United States Government Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I acknowledge that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work.&#160; I agree to be bound by all such obligations and restrictions which are made known to me and to take all reasonable action to assist the Company in discharging the obligations of the Company under such agreements.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;13.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Remedies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I acknowledge that my failure to comply in all material respects with, or my material breach of, any of the terms and conditions of this Agreement shall irreparably harm the Company, and that money damages would not adequately compensate the Company for </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">this harm.&#160; Accordingly,&#160;I acknowledge that in the event of a threatened or actual material breach by me of any provision of this Agreement, in addition to any other remedies the Company may have at law, the Company shall be entitled to seek equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy then available, without requiring the Company to post any bond.&#160; I agree that nothing herein contained shall be construed as prohibiting the Company from pursuing any other remedies available to it for such threatened or actual breach, including money damages, and I agree that the Company shall be entitled to recover from me any attorney&#8217;s fees it incurs in enforcing the terms of this Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;14.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Not an Employment Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I acknowledge and agree that this Agreement is not a contract of employment for any specific period of time.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;15.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Reformation and Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; If any provision of this Agreement is held to be invalid or unenforceable under applicable law, such provision shall be reformed and&#47;or construed, if possible, to be enforceable under applicable law&#59; otherwise, such provision shall be excluded from this Agreement and the balance of the Agreement shall remain fully enforceable and valid in accordance with its terms.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; No delay or omission by the Company in exercising any right hereunder will operate as a waiver of that or any other right.&#160; A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Reassignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof to whose employment I may be transferred, without the necessity that this Agreement be reassigned at the time of such transfer.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(d)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Applicable Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (but not the law or principles of conflict of laws).&#160; The parties submit to the exclusive jurisdiction of the state or federal courts of Delaware for all disputes arising out of or relating to this Agreement, and hereby waive, and agree not to assert, in any action, suit, or proceeding between the parties arising out of or relating to this Agreement that the action, suit, or proceeding may not be brought or is not maintainable in such courts, that this Agreement may not be enforced by such courts, that the action, suit, or proceeding is brought in an inconvenient forum, that the venue of the action, suit, or proceeding is improper, or that the action, suit, or proceeding, if brought in Delaware state court, may be removed to federal courts.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(e)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; This Agreement shall be effective as of the date of my Employment Agreement with the Company, shall be binding upon me, my heirs, executors, assigns and administrators, and shall inure to the benefit of the Company and its successors and assigns.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(f)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; This Agreement, together with my Employment Agreement with the Company, contains the entire agreement of the parties relating to the subject matter herein, and may not be waived, changed, extended or discharged except by an agreement in writing signed by both parties.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;(g)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Acknowledgement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; I acknowledge and agree that I have fully read and that I understand all of the terms and provisions of this Agreement, that I have had the opportunity to consult with an attorney and to discuss this Agreement with an attorney, that I have had any questions regarding the effect of this Agreement or the meaning of its terms answered to my satisfaction, and, intending to be legally bound hereby,&#160;I freely and voluntarily sign this Agreement.&#160;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROCKWELL MEDICAL,&#160;INC.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Russell H. Ellison, MD</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; President &#38;CEO</font></div><div style="margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Executive</font></div><div style="margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Russell L Skibsted</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT&#160;I</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The following is a complete list of all inventions or improvements (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Intellectual Property&#8221;) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">relevant to my employment by Rockwell Medical,&#160;Inc.&#160;(the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) that have been made or conceived or first reduced to practice by me, alone or jointly with others, prior to my employment by the Company that I desire to remove from the operation of the Employee Confidentiality, Assignment of Inventions, Non-Interference and Non-Competition Agreement between me and the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Employee Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9744;No Intellectual Property.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9744;Any and all Intellectual Property regarding&#58;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9744;Additional sheets attached.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; I propose to bring to my employment the following materials and documents of a former employer or materials and documents created by me and&#47;or others during any previous employment (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#58;&#160;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9744;No Materials.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9744;Materials&#58;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9744;Additional sheets attached.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; I acknowledge and agree that the Materials set forth above are being provided by me in accordance with the representations set forth in Section&#160;6 of the Employee Agreement between me and the Company.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Signature</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Russell L. Skibsted</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT C</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SEPARATION AND RELEASE AGREEMENT</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Separation and Release Agreement (the &#8220;Agreement&#8221;) is made between Rockwell Medical, Inc., a Delaware corporation (the &#8220;Company&#8221;), and &#91;_________&#93; (&#8220;Executive&#8221;, and together with the Company, the &#8220;Parties,&#8221; and each a &#8220;Party&#8221;).  Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Employment Agreement, dated as of &#91;________&#93;, 2020, by and between the Company and Executive (the &#8220;Employment Agreement&#8221;).</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.&#160;Executive&#8217;s employment ended, effective &#91;           , 20  &#93; (the &#8220;Separation Date&#8221;).  Effective as of the Separation Date, Executive automatically resigned from any appointed or elected positions with any Released Party (as defined below), and Executive will cooperate with the Company to effectuate such resignations.  The Company has provided Executive his accrued base salary through the Separation Date, and Executive is not owed any additional amount from any Released Party except as set forth herein.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2. &#160;Provided this Agreement has become effective, that Executive&#8217;s representations set forth herein are accurate, and that Executive continues to abide by his obligations to the Company, the Company will provide Executive with the severance amounts and benefits set forth in Section 5(b) of the Employment Agreement (collectively, the &#8220;Severance Benefits&#8221;) in accordance with the terms of the Employment Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.&#160;Executive, on behalf of himself, his heirs, successors, assigns, and any individual or entity that could assert a claim through him or on his behalf relating to Executive&#8217;s employment or termination of employment with the Company, fully and forever releases, acquits and discharges the &#8220;Released Parties&#8221; (defined as the Company, all of its past and present affiliates, parent companies, subsidiaries, investors, predecessors, successors, assigns, and related companies and entities, and all of their past and present shareholders, members, managers, partners, directors, officers, supervisors, trustees, employees, attorneys, persons and agents and all other persons and entities acting in connection with any of them) from and for all manner of claims, allegations, suits, charges, administrative actions, litigation and&#47;or causes of action of any type, based upon any fact or set of facts, known or unknown, existing from the beginning of time through the date this Agreement is signed by him (the &#8220;Released Claim(s)&#8221;).  Without limitation and for illustration purposes only, the Released Claims include claims for or relating to&#58;  monetary damages and relief and&#47;or recovery of every type&#59; wrongful discharge&#59; breach of express or implied contract, including regarding the Employment Agreement&#59; any severance policy or plan&#59; any incentive equity plan, policy or agreement&#59; attorneys&#8217; fees and costs&#59; retaliation, discrimination and&#47;or harassment related to any protected characteristic or activity&#59; Title VII of the Civil Rights Act, the Age Discrimination in Employment (&#8220;ADEA&#8221;), the Older Workers Benefit Protection Act, the Americans with Disabilities Act, and the Employee Retirement Income Security Act&#59; and all other federal, state, common or local statutes, ordinances and laws.  Notwithstanding the foregoing, Executive is not prohibited from making or asserting&#58; (i) Executive&#8217;s rights under this Agreement and any claims arising from the breach of this Agreement, the Employment Agreement or any equity award agreement by the Company, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">including any claim for breach of Company&#8217;s obligation to make the payments described in Section 2 above&#59; (ii) Executive&#8217;s rights, if any, to indemnity pursuant to the Company&#8217;s articles, bylaws, or any indemnification agreement between the Company and Executive and&#47;or to the protections of any director&#8217; and officers&#8217; liability policies of the Company and (iii) if Executive owns an equity interest in the Company, his rights as an equity owner.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.&#160;The Parties intend that the general release by Executive will be construed as broadly as possible.  Executive agrees not to commence or pursue any legal action regarding any Released Claims, provided that this Agreement does not limit his right, where applicable, to file or participate in an investigative proceeding of any federal, state or local governmental agency.  To the extent permitted by law, Executive agrees that if such an administrative claim is made, he shall not be entitled to recovery of individual monetary relief or other individual remedies, provided that nothing in this Agreement limits his right to participate in the Securities and Exchange Commission&#8217;s (&#8220;SEC&#8221;) whistleblower program and receive a whistleblower&#8217;s award thereunder.  The Parties further acknowledge that the Company and its affiliates are not releasing any claims against Executive or any other individual, and all rights as to such claims are reserved.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.&#160;Executive represents and warrants that&#58; (a) he has returned all Company property, information and files in his possession, without retaining copies of same&#59; (b) he has complied with the Employee Confidentiality, Assignment of Inventions, Non-Interference and Non-Competition Agreement between Executive and the Company dated as of &#91;_________&#93;   , 2020 (the &#8220;Restrictive Covenant Agreement&#8221;)&#59; and (c) he has not assigned any Released Claims.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.&#160;Executive will cooperate with the Company in providing information with respect to all reports required to be filed by the Company with the SEC as they relate to required information with respect to him.  Executive acknowledges and agrees that the Company may be required to file a copy of this Agreement with the SEC.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.&#160;Executive acknowledges that he remains bound by, and will comply in all material respects with, his post-employment obligations to the Company, including but not limited to those set forth in the Employment Agreement and the Restrictive Covenant Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.&#160;Executive acknowledges and agrees that, pursuant to the requirements of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (&#8220;Section 954&#8221;), certain payments received by Executive may be subject to &#8220;clawback&#8221; in the event the Company is required to prepare an accounting restatement of its applicable financial statements due to the Company&#8217;s material noncompliance with applicable financial reporting requirements.  Executive agrees to promptly return to the Company the amount of any compensation paid to him that is required to be forfeited in accordance with Section 954.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.&#160;Executive acknowledges that the Company&#8217;s promises set forth throughout this Agreement would not be provided unless Executive executed this Agreement and are each separate and adequate consideration for this Agreement, including Executive&#8217;s release of claims.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.&#160;To the fullest extent permitted by law, and except as to statements made in legal, administrative or arbitral proceedings in disputes between Executive and the Company and truthful testimony, Executive agrees that he will not make public statements that defame, disparage or otherwise publicly speak of the Company or its present or former officers or members of the Board and&#47;or its products or services in a false or misleading manner, including but not limited to through any media, social media, Facebook, Twitter or similar mechanism.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.&#160;To the fullest extent permitted by law and at the sole expense of the Company, Executive agrees to reasonably cooperate with the Released Parties in any internal investigation, any administrative, regulatory or judicial proceeding or any dispute with a third party that he had knowledge of while employed by or providing services to the Company.  Executive&#8217;s cooperation may include being available to the Company upon reasonable notice and subject to Executive&#8217;s personal and professional commitments, for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, and turning over to the Company all relevant documents which are or may come into Executive&#8217;s possession.  If Executive is served with a subpoena or is required by court order or otherwise to testify or produce documents in any type of proceeding involving the Company or its affiliates, he must advise the Company within ten (10) days of same and reasonably cooperate with the Company in objecting to such request and&#47;or seeking confidentiality protections.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.&#160;This Agreement does not constitute an admission by the Company that any action it took with respect to Executive was wrongful, unlawful or in violation of any local, state, or federal act, statute, or constitution, or susceptible of inflicting any damages or injury on Executive, and the Company specifically denies any such wrongdoing or violation.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.&#160;In addition to any other legal and&#47;or equitable remedies, if Executive materially breaches any material provision of this Agreement, the Employment Agreement, the Restrictive Covenant Agreement, or any other contractual or legal obligation Executive owes to the Company, then the Company may cease paying and&#47;or providing the Severance Benefits and Executive will be required to repay and&#47;or forfeit any Severance Benefits received through the date of such breach or discovery of the inaccuracy of his representations, provided that Executive may retain $1,000 of such payments.  The exercise of such remedies will not affect the validity of the release and other obligations of Executive as set forth in this Agreement or otherwise, nor will it limit the other legal and&#47;or equitable remedies otherwise available to any Released Party.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.&#160;This Agreement and the rights and obligations of the parties hereunder will be governed by, and construed and enforced in accordance with, the laws of the state of Delaware, excluding any such laws that direct the application of the laws of any other jurisdiction.  The Released Parties are intended third party beneficiaries of Executive&#8217;s obligations under this Agreement.  </font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.&#160;This Agreement will be enforceable to the fullest extent permitted by law.  If any provision is held to be unenforceable, then such provision will be construed or revised in a manner so as to permit its enforceability to the fullest extent permitted by applicable law.  If such </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">provision cannot be reformed in that manner, such provision will be deemed to be severed from this Agreement, but every other provision of this Agreement will remain in full force and effect.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16.&#160;This Agreement may not be amended, modified, waived or terminated except in a writing signed by Executive and the Company&#8217;s signatory to this Agreement or his successor.  Further, the waiver by a party of a breach of any provision of this Agreement by the other will not operate or be construed as a waiver of any subsequent breach of the same or other provision of this Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">17.&#160;Except as otherwise provided herein, this Agreement will be binding upon and inure to the benefit of the parties&#8217; respective successors, permitted assigns and transferees, personal representatives, heirs and estates, as the case may be&#59; provided, however, that Executive&#8217;s rights and obligations under this Agreement may not be assigned without the prior written consent of the Company.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">18.&#160;Executive has had 21 calendar days to review and sign this Agreement and is advised to consult with an attorney of his choice before signing this Agreement, which includes a release of potential claims under the ADEA.  Executive understands that he may use as much of this 21-day period as he wishes prior to signing.  Changes to the Agreement, whether material or immaterial, will not restart the review period.  Executive may expressly and voluntarily waive any part or all of the 21-day review period by signing and returning this Agreement prior to the expiration of the review period.  Executive has the right to revoke his release of any and all ADEA claims by informing the Company of such revocation within seven calendar days following his execution of this Agreement (the &#8220;Revocation Period&#8221;)&#59; for the avoidance of doubt, no claims other than those arising under ADEA may be revoked during the Revocation Period.  Any such revocation must be in writing and delivered to the Company in care of its signatory to this Agreement or his successor.  This Agreement will become effective upon execution by Executive with respect to all claims other than those arising under ADEA, and will only become effective with respect to the release of ADEA claims if the Revocation Period has expired without any revocation having been delivered in writing to the Company within the Revocation Period.  In the event that Executive revokes this Agreement with respect to ADEA claims, the Company shall make a single payment of $1,000, at which point Executive will be entitled to no further payments or severance benefits hereunder or under the Employment Agreement. Upon the expiration of the Revocation Period without the revocation of the ADEA claims, this Agreement shall be deemed to have become &#8220;final, binding and irrevocable,&#8221; as set forth in Section 5(b) of the Employment Agreement.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">19.&#160;This Agreement reflects the entire agreement of the parties relative to the subject matter hereof, and supersedes all prior, contemporaneous, oral or written understandings, agreements, statements, representations or promises regarding the subject matter hereof, provided that this Agreement does not supersede or modify the Employment Agreement, the Restrictive Covenant Agreement and those agreements pertaining to Executive&#8217;s equity holdings.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">20.&#160;This Agreement may be signed in counterparts, and when this Agreement has been signed by all parties, each counterpart shall constitute an original, notwithstanding that </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">fewer than all of the parties&#8217; signatures appear on any one counterpart.  An electronic signature transmitted by facsimile or other electronic means shall be deemed to be an original.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font><br></font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">&#91;Signature Page Follows&#93;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The parties hereto confirm their agreement by the signatures shown below.</font></div><div style="text-indent:36pt;margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Rockwell Medical, Inc.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; </font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; </font></div><div style="text-indent:36pt;margin-top:12pt;"><font><br></font></div><div style="text-indent:36pt;margin-top:12pt;"><font><br></font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:0.36pt;margin-top:0.12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">30</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex-rmtix20200915xrsxcf.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia1a56d389eae4690b70828057f5570fd_1"></div><div style="min-height:72pt;width:100%;"><div style="margin-bottom:8pt;"><img alt="reexhibit991image111.gif" src="reexhibit991image111.gif" style="height:58px;width:238px;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#160;&#160;&#160; </font></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:18.803%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.964%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.803%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.964%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.966%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Rockwell Medical Announces Appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer and Chief Business Officer</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;">WIXOM, Mich., September 15, 2020 (GLOBE NEWSWIRE) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">-- Rockwell Medical, Inc. (Nasdaq&#58; RMTI) (&#8220;Rockwell Medical&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the appointment of Russell L. Skibsted, M.B.A., as Executive Vice President, Chief Financial Officer (&#8220;CFO&#8221;) and Chief Business Officer (&#8220;CBO&#8221;), effective September 15, 2020. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">In this new role, Mr. Skibsted will be responsible for business development, financial operations and investor relations for the Company and will oversee the Finance and Accounting, Legal and Compliance, and Human Resources and Administration functions, reporting to the Chief Executive Officer and Board of Directors. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;"> </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">&#34;We are pleased to announce Russell&#8217;s appointment as CFO and CBO of Rockwell Medical. His more than two decades of life sciences industry executive experience, including roles as CFO and CBO of publicly-traded biotechnology companies, are an excellent match for our Company as we focus on transforming our business through executing our commercial and worldwide business development strategy for Triferic and Triferic AVNU in kidney dialysis, and prioritize the development potential of our </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;">FPC </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">platform to address iron deficiency and iron deficiency anemia in other medical indications,&#8221; said Russell Ellison, M.D., M.Sc., President and Chief Executive Officer of Rockwell Medical. &#8220;Russell will be a dynamic contributor to our leadership team, and we warmly welcome him to the Company.&#34;</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">&#8220;I am honored to join Rockwell Medical at this pivotal time for the Company and look forward to working with the executive team and other stakeholders to strategically advance the business and bring value to patients and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;">stockholders</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">,&#8221; said Mr. Skibsted. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">Mr. Skibsted is a seasoned executive with more than 25 years of experience in finance, global business development, capital raising, investor relations, and operations. He has worked with a variety of both public and private life sciences companies, from commercial stage, development stage and start up. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">Prior to joining Rockwell, he served as CFO of AgeX Therapeutics (NYSE American&#58; AGE) , a biotechnology company focused on cell therapy targeting the diseases of aging that was spun out of BioTime, Inc. (currently Lineage Cell Therapeutics, Inc. (NYSE American and TASE&#58; LCTX)). Previously, Mr. Skibsted served as CFO of BioTime, Inc., a publicly-traded biotechnology company which he joined in 2015, where he simultaneously, from time to time, performed the role of Chief Financial Officer for several of BioTime&#8217;s public and private subsidiaries, including Agex Therapeutics, OncoCyte Corporation (NYSE American&#58; OCX), a developer of novel, non-invasive tests for the early detection of cancer (November 2015 through November 2017) and Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine with clinical programs in spinal cord injury and oncology immunotherapy (March 2016 through November 2016). Prior to BioTime, Mr. Skibsted&#8217;s served as CFO or Chief Business Officer for several public and private life science companies, including Proove Biosciences, Aeolus Pharmaceuticals, Spectrum Pharmaceuticals and Hana Biosciences. From time to time, he also acted as a consulting CFO to various life science companies as Managing Director of RSL Ventures. Earlier in his career, Mr. Skibsted&#8217;s held roles as Portfolio Management Partner and CFO at Asset Management Company, one of the oldest and most respected venture capital firms in Silicon Valley, and Vice President for GE Capital Services Structured Finance Group. Mr. Skibsted holds a B.A. in Economics from Claremont McKenna College and an M.B.A. from the Stanford Graduate School of Business.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">About Rockwell Medical </font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-bottom:8pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:8pt;"><img alt="reexhibit991image111.gif" src="reexhibit991image111.gif" style="height:58px;width:238px;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#160;&#160;&#160; </font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company&#8217;s initial focus is the treatment of anemia in end-stage kidney disease (ESKD). Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates&#47;dialysates to dialysis providers and distributors in the U.S. and abroad. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">About Triferic Dialysate and Triferic AVNU</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management - with the potential to become the future standard of care. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to the bone marrow and maintain hemoglobin without increasing iron stores (ferritin). Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body) upon entry into the blood which is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no reports of anaphylaxis in over 1,000,000 patient administrations, addressing a significant medical need in overcoming Functional Iron Deficiency (FID) in ESKD patients. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Important Safety Information </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and&#47;or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving Triferic in two randomized clinical trials. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Iron status should be determined on pre-dialysis blood samples. Post dialysis serum iron parameters may overestimate serum iron and transferrin saturation. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">The most common adverse reactions (&#8805;3% and at least 1% greater than placebo) in controlled clinical studies include&#58; procedural hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain in extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%), asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Triferic&#174; is a registered trademark of Rockwell Medical, Inc.</font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;">Notice of Issuance of Inducement Grants</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-bottom:8pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:8pt;"><img alt="reexhibit991image111.gif" src="reexhibit991image111.gif" style="height:58px;width:238px;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#160;&#160;&#160; </font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;">Pursuant to his employment agreement, Mr. Skibsted will be awarded stock-based compensation representing the right to acquire shares of common stock (the &#8220;Inducement Grants&#8221;). The Inducement Grants will consist of options to purchase up to 750,000 shares of common stock, subject to 600,000 of which are subject to time-based vesting conditions and 150,000 of which are subject to performance-based vesting conditions. The Inducement Grants will be issued upon Mr. Skibsted&#8217;s commencement of employment (the &#8220;Grant Date&#8221;), and all stock options included within the Inducement Grants will have an exercise price equal to the fair value of the common stock on the Grant Date. The Inducement Grants have been approved by the Company&#8217;s Board of Directors and the Compensation Committee of the Board of Directors. The Inducement Grants will be issued outside of the Company&#8217;s stockholder-approved equity incentive plans as an inducement grant, in accordance with Nasdaq Listing Rule 5635(c)(4).</font></div><div style="text-align:justify;"><font><br></font></div><div style="margin-bottom:9pt;"><font><br></font></div><div style="margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">CONTACTS </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Investors&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Argot Partners</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">212.600.1902</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Rockwell&#64;argotpartners.com </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Media&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">David Rosen</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Argot Partners</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">212.600.1902</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">david.rosen&#64;argotpartners.com</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-bottom:8pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rmti-20200915.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e7c61a3a-ab90-4f6d-83a6-780a6ceb1f1e,g:5f5e7233-c5fd-4f3c-a1b5-51621a270ca9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rmti="http://rockwellmed.com/20200915" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20200915">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20200915_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20200915_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20200915_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20200915_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://rockwellmed.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>rmti-20200915_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e7c61a3a-ab90-4f6d-83a6-780a6ceb1f1e,g:5f5e7233-c5fd-4f3c-a1b5-51621a270ca9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:type="simple" xlink:href="rmti-20200915.xsd#Cover"/>
  <link:calculationLink xlink:role="http://rockwellmed.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>rmti-20200915_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e7c61a3a-ab90-4f6d-83a6-780a6ceb1f1e,g:5f5e7233-c5fd-4f3c-a1b5-51621a270ca9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:type="simple" xlink:href="rmti-20200915.xsd#Cover"/>
  <link:definitionLink xlink:role="http://rockwellmed.com/role/Cover" xlink:type="extended" id="i44c82e4fca364a3793ff0c3f0c1bbaf0_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>rmti-20200915_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e7c61a3a-ab90-4f6d-83a6-780a6ceb1f1e,g:5f5e7233-c5fd-4f3c-a1b5-51621a270ca9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_8865d90b-dcc3-4297-be91-fc97750b67b4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_13fd7bd5-7ba6-4cd0-85f3-513c4e3a6865_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b966c317-7598-4a6c-95dc-b5731b4afb36_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c1cb2a3b-9aeb-44dc-899a-9de03c6cff47_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d394bd67-fd4f-47c6-883e-0bc71a4aa8e1_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7212eabb-8782-4a0b-83e6-b24df093822f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_895d4d92-08de-437d-8eab-7c96c3d47bc0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_656ef481-2a71-4c99-be8c-2a7085c00bcc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5d97113b-7d8d-4dea-8f92-4ae0df592300_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c868eb18-c25a-4176-94da-a43177af4891_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_58f82eb8-10f2-4bc4-92b1-a24ab178801b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_33adcb57-d80f-4e5c-ae06-a583ea34d6ab_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_768cbfdb-988e-4cc2-85a6-e54d492dc742_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2fbe495e-1c0e-4208-a9c3-086088d89b21_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cd877e12-93b6-4907-8438-236861ceeefb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_753c28ee-664b-4658-bec8-aac7dad8c82a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_cd003298-7d13-4d78-a540-fd3bb21b9be5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4bfde2bd-34df-45ca-9200-5f8a20561450_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c8fd6c54-593c-4ddf-8436-c9988f33a1e4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_231178c4-fb68-40b7-8e84-da51dca72863_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_564c1d29-590d-4d12-88e7-7cb2e1dfb778_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bc73b2d5-8965-4a9d-9974-864e6213554c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a3ffdcd7-a4b2-4df8-9a58-9af88da3f74a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>rmti-20200915_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e7c61a3a-ab90-4f6d-83a6-780a6ceb1f1e,g:5f5e7233-c5fd-4f3c-a1b5-51621a270ca9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:type="simple" xlink:href="rmti-20200915.xsd#Cover"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8cc2c48f-5fed-4c06-96b5-67fcd92c4cc8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_DocumentType_8cc2c48f-5fed-4c06-96b5-67fcd92c4cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bd05b11e-6a77-4dde-8c78-4f21c611c18b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_DocumentPeriodEndDate_bd05b11e-6a77-4dde-8c78-4f21c611c18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e6201de1-39d0-4279-9c88-52df705c3048" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityRegistrantName_e6201de1-39d0-4279-9c88-52df705c3048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c1570546-9d71-4d02-86bc-ba8316352986" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c1570546-9d71-4d02-86bc-ba8316352986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ecff8217-de17-4d42-bb09-e539b9507765" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityFileNumber_ecff8217-de17-4d42-bb09-e539b9507765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e83e779b-2a3a-4e6f-b302-ef8825ab9db0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityTaxIdentificationNumber_e83e779b-2a3a-4e6f-b302-ef8825ab9db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_eb56a102-253d-4a14-bdbe-7f3c5c0f62df" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityAddressAddressLine1_eb56a102-253d-4a14-bdbe-7f3c5c0f62df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_66fe0b78-6b74-4862-9160-4ce31ca1fdd8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityAddressCityOrTown_66fe0b78-6b74-4862-9160-4ce31ca1fdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_132ffaf3-d2a8-48af-80b4-e923dc431fe5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityAddressStateOrProvince_132ffaf3-d2a8-48af-80b4-e923dc431fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a334e841-2048-4d31-ac28-5da22cbf947d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityAddressPostalZipCode_a334e841-2048-4d31-ac28-5da22cbf947d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_519477c9-6061-4a2d-8fc0-a402bef36428" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_CityAreaCode_519477c9-6061-4a2d-8fc0-a402bef36428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3d27267f-767f-43a0-944d-81d67e453a26" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_LocalPhoneNumber_3d27267f-767f-43a0-944d-81d67e453a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5c4a2f74-f6d0-465c-b72f-bf78d37831fc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_WrittenCommunications_5c4a2f74-f6d0-465c-b72f-bf78d37831fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_76033078-7c70-427c-a450-c7e1ea9e93ab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_SolicitingMaterial_76033078-7c70-427c-a450-c7e1ea9e93ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1e0d2754-99a9-4d69-bd10-ac834e361930" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_PreCommencementTenderOffer_1e0d2754-99a9-4d69-bd10-ac834e361930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d07e4271-35af-4410-87af-9d4094da96e0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d07e4271-35af-4410-87af-9d4094da96e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b1802c74-b654-4557-80f5-cfcfcead8a70" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_Security12bTitle_b1802c74-b654-4557-80f5-cfcfcead8a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1caf2ad4-2a49-48b9-bd45-0293348a6608" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_TradingSymbol_1caf2ad4-2a49-48b9-bd45-0293348a6608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b435244b-3506-4f02-9b74-909af4561cfc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_SecurityExchangeName_b435244b-3506-4f02-9b74-909af4561cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_842f80c5-df27-4eb5-bf34-83d2202a9959" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityEmergingGrowthCompany_842f80c5-df27-4eb5-bf34-83d2202a9959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f5d5ae11-15c7-472d-93f4-50a5222f5c5f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_EntityCentralIndexKey_f5d5ae11-15c7-472d-93f4-50a5222f5c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_28388835-865c-4005-87d9-9cadc5b96a54" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb94848f-98f3-4d92-8ca3-ce637a2cb109" xlink:to="loc_dei_AmendmentFlag_28388835-865c-4005-87d9-9cadc5b96a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>reexhibit991image111.gif
<TEXT>
begin 644 reexhibit991image111.gif
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M0Q8\J&BC#B !-GR#(=D0E;&D7BOA1EH8/8#GL0@ YF:5R^U =&E0 R"  O!
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M <!X3, -O1,+2Y! M2-[?1$+( .(4_^"/!83>8(T*S=##='C@:,G5#W0"=>
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MR1(X(5K(A5)@.JCC1Q>T"ZCP52O""JC0#$HID(9Z"XNP!M6D?),PG'YE0L;
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M)&()9Y^QIO$!M36GK'*Q)1PCK@ (+!PQ'@S]([!#FP)<$[+C"-!409@Z:;#
M &4%#SQ<D[AFJ=(> #99V#[$SD9G\:IGF456V&",1LP9+!=#N(A"BC-NV2;(
M9P?"!Y]^RFED#!-0R",7Q2SJ!Y]EZH ""C)P60<?R_11!YMJJ*&FFG^%J88;
M=3QUUB!PJIDF8($?GD88;!"US*!OA(GE$T\ZT:0J-C;IY)-89*DF'(K'Q<L@
M;# NJ1.70Q99%FJ^B><Y&_4)QU^'!9ZF&G#B05C$?N@)YYJ&'X98%F%H#AHL
ME7O^-^!O_TX.RY]XL $X:VHF'E>?JY$&.VRQQPZ;FIZQ 9,@A1G>F6RW'\ZZ
M&FS2>>Z>?AMN&V"D]7X;;&Q^;AIEP0MB9YUYY#&G&\.9[,<<6_X(8PH9IJBC
M$5VB,<>=>LKMI_-^]BE7'GGP62<7/D[0H(MKQ2KKEC"07".7? >GO7;;;\<]
M=]UWY[UWWW\'/G@;HX4$AA2Z""S>P EOQI9%Z@B#BRRDD*)>&:ZG 0HI:NBB
MCDS8&7).@OJQQYE&TJ@>#$;*$5]X]]^'/W[YG=ZG?OOW\?SS??31I_VO],=?
M_CI'NP'.KW?U,V#NRF&(&EP@!8M0ACQ\AP]WE(,7A8 1%+CP!_]>F$-?"01A
M"$6(.X.49@@[J0;5+$*/:GQB"2?,#UX8HQF<-,"&-\2A#1^PG%*!11V?D,YL
M#L  (C+ AGLBP(?8((MPV$PLC'%,"63A1*>I8QJ?,,T#$F"  QP  0@X@ -X
MD 2D,$U$YVD0@F(!G_WH0Q822  /-B&I$8Z+?.8JTB!6\($Q?(](ZW#'Z/ G
MEGCAHQ[N, <T=&$)/V0P"V3XPRJV40__U=&2E\3D1<3D"0EP22$2^(1S, (.
MF="0-JP2"S5X<( &#*$:M6-0 R8@#+&$ X@.^- <\<*-4QU@ K)8GD7T(8S&
M,, !/NC$-("&$9S%@@DPU$]>*-4;" C_(4N:6F,;93&!#W&"CID<%^GR98]R
MX((.-[#"%*#PA.MI;RY94.?UD.1.,)"A#H98Q3+8\4%P]M.?_MQDGN 4BTU
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M'ABP>)!!C(B.Z>B,2_2$3+P(?<"&3O"!)P$.URB.2^P$:@ I:J /Z@@/ DB
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M@5<H0..<CQ%5EMD8E ,\$]!\D(<P+ *[B-M<#P#0S8'XKQA]#.MTQ0!X@"7
M+;^ZB'V@AU@H@2-EB$>)E,Z4#H:L"0C8A(HD2>E(C9UD !_8RA7J#X$TTX\P
M /_Q7!#R[(SSU)7!B0>RA(WVW"_R688^B (9$(-;<$NRD(93B(,<F -)* =[
M:(=VJ =HA!<*@H;'4;@J6(-,<(8(O8AX:89^PP$^>(:Y^T?'6!-<&2.>&(J>
M*(JLR#H#TXQ9.4;SRDY9\ $&:!0/Y1*O&@(V +M9Z!FC8YE.6((5O)3*-,]5
M44:Z>X55^E+82*(2V(E7H 6YT2U_P1A/8(,,2]%,&8)/^ :-NDU;245UN =L
M\,!99$/.T$SF(#VQX(:6^@\NX0&:^@J)BE45#8 %D".ATH>LZB3+K"HCF\,R
MA0U-X8I8>(6!)=B"-=B#)=A8J(;+^H>N;-.P7$8Y=<;_CU+4?R(,PYB"-) $
M;/F*\H&$%^@ *S $CD69>#$';>$"**B"/N"%V1D?>TB&,>@ #Y@#:.!4@*P)
M^4JAMN+9GO79GKT:3G2 AX2*S?0K=4B%*[U,J% B6?@&=9 '?0@F?:"'> B'
M:FC !LA(V&B/]VBL2BE2H@52']@$IX6K$]L'PA,';) %39@)AX@C-J@&)NU2
MH?0(!$&*3YB)>)52G"B!39"QO-#./ME1Q,(94\S118S.,84)5E3<  "E@\&(
MP9W3->J?^\%<S)7:^N&?^VD?AZV)"GE3P7&5#)G80>PLM/2#A2,#/HU'0](<
M=FB&9("&;*P=?"B'5? #A5,?_\$@BT2"ALSI1[#HU/3(S<UR%A;JA BPE>NL
MR&D( C190_Q8V-G[!R<%AU<8@B<1$"F!@"70%8,H5KZ-#4TA3EP<D:'!AE?0
MA"0XK($KR86$B -I/LW8$#8Y)N)DV,02AK0:@%%9E=&ESOIHWC[1TE@<"%"1
MW@FID&'MUZ@LRU"BA_VY'_[9W J66A'3JS9%D-%%F=)M1O:DV/W"!V]8!1C)
M D/P78MPAUOX@S'( UPH5.NU##O=W9:3A$D=#&.0A#_86,O(T-?XC%?HF\JS
M.M5$%38$I2:Z5\2%C<\0!KK5/EOB@49A#7:]Q7^8KJ$-CCC"J W$"ZI]*VC<
MUJFL2O\N*8%/.%<K8=/.J,41_H<9PDUEL8XJ?<IK(*WAP*;]?4I_[8P#4 X>
M$.1!)N1"%F0?2 )^Q0O0_0C1%4N)%6'4A2JXD(L43@R,,(=%T (,8 %(B 9*
MW1V4:X243>$5)@AO2 0<J(%[<=DG JQ8:9/INT 7? "3--+9$%.WB%.G4%R^
MXE+!(:5>P10)\(1OH+K'2H M"<\*>Q\?-=)U=>.O.LV;P5>B#0#\P(V#R%=K
M]E"HB"UA$ W'X@$%,-+PE 63HEP.&0#07.=UA@TWM0Q&-A"('9S>1)9AAF//
MLN$JL!?7)0MVR+1=.(96YIU^< 8_D (:((-<N-"!8(=2J /_*^ ""&(N5_94
MV+Q?#N7(R^S6I9B/$/X(*3(I&]EEJ:1*"" I>H B ]A#\^Q@^?'1$I45%L56
M,/X*U;)?F43&:V!& ID-"1@"(="2]2#F;%6E+PT/7W+*R?7C,V5#1\X+>?Y*
M>DY/7>Q%.HU&:3CAZUF#9@B<=:"$/5@$5# '&AX7N*@#*9AH8W@'BQ!E,*B"
M.E@%\&FNBU;$$AW*'^V0 FBE<Y8NG )IAIB 6)#B#YX&38 5]0  E%8F-&S3
M (9I+Q5;+-60\&(K9Y&/ZG1&D3&-!B 0*)8%8ZW$:R8C6> DQ5WL+1WI=';J
MQT;/WYJ)AWWM<;'GQ\5JSK('96 $_U)6X45=AC.@@1K0 \D4GGIPADD  RF(
M5+HF%W-P'2CX@D4@V;^R:\56$S-^C0,)@IHF4PB.3;[B3-H9X+(LYF]MJ5@Y
M !^8ALBVY>.(E0/A7BF%"*7NH?TP""@]UH8 Y#RQY0(Q7W40YV3>0UP!0%19
M#YP04SED;5YT30 A  5PI7ANXT9^:=JQY[+,Y\YRAUP(A.DA@Q]6&[X@ RBX
M@I%UG]:!D8F>;B+I!3*8G#\P9>)]Y>ZM2@V-DI].9&%88X+@%\2URJ8T2F=!
MPUZTQ8J(I8U$TB7BXV>)TUD0AQ/;5N^\Q$T AM*P% XA@ <8SNS;#TKQ1&@>
MR"6FVFHHJ/\S#=*Q6/ I)903(@*+<O,WKRCWK4W8+D]XMO"F_HC;AJH6WMTI
M6&Z+P-WG#H/5$9Y]>,\1GP(8AY?<3@,D\0-HD*$95T10U825. E-^$ #^%&'
M0'!W%0M0Z6\V^2H>9?+YV,[LANP^-MUCI%=L+6RAB8=J,$1"Z83=M(CX'0Z:
M3*'/D8\@F [OS E-F&;!%0;$[DX:#Z_9VH?^/8#_!9 (<0@QQXLT7PA0RH9P
M4(=LU_9MY_9LSR\)C^W0K?!ZAN2HT/.GXG-X^G.""'08&?3I_AWR,88Q\  K
M((05S^TR<'1OB/3J7@CYP@8+%G@++L5M-M*0\ 3WLE('6<0'GXS_;&J5TOA,
MPE5R'@]M$EU1,1HPR64\<)C %=3:/ZD-1;9-+_WL\4!?(?V&3Y@ \GT*%HT3
MF[Y>9@>.".D,;&XL9";-]:B0GQ0+:H?<+.X=J7;IV7Z6VGZ07ZK83+K8Z2F#
M25@'>#GT)TCT&/<=2]V#,3 #28CZ\3ET**AZ&3H5^8T,2 ERBQCOT?[*"?"$
M\,:(?I"/*NY0FT@.!/L$88@[L+B'<! &+/(!.'+YFP@)<)[!5" " NZ3!U>.
M6OT$DGG:MWHKPQ.&5^#5[WN !9AC5U25X<R&YRACU0"J9HF/8%AU#DX"P@=W
MFAA-X9!V@J '/%Y/6@F/@[(,[0Q("."$_Z41AW  AW#P?=[O_=\/?M\?KM\'
M?FR_+*DNS1[X!+Z)&KC1FK:1FW.%RGN&D,7NA%D0!N<OXJ/+//EY!V-8!-Z&
M=X-> ZY>AOH$'GQH!PIEAZ;!AVTH!7<G=(L.VRE=CK.WB'L@)@C(R-8 B (/
MDE3[9_ @PGBQDC@(  !  (</(08@<, !! D\@B1APH8-DR1#>$B X.  @8@J
M):J4T G;/80'Z0DC\J" RH<K55IL\""CA*!"(3QPT !E1)TY)P8PP.-3-GT&
MJPUI@',E  8\-H&3B7 ?N$]#&B[5F75K5Z]J]865L/-M10=#"GK5)\P'TIU,
M*_*(14\M8)IL'O\HE0B 0 .@0A<S;NQX@H].:0V&Z\2# <65 RY"Z.SY,VC0
M$DJPX68P'BTV$ KK1/PS-&S8)9)X$@?X-N[<:O%!RQ1&QI,ZSOK)--<H#!0P
MDYS9T^T\=S][SQ;M682+G==YQA9QR>+G%O;<V)) .%#V .G)N=E^<LMRIP,D
MG]3=UG=-TV6*$S/O)%#@ ( '%) 27/M1], 2L=!77U@\)$#@>TGQIQ=K^TF8
MU&82+/$*.%(9=$U5*166  ^2Y49/-6Q<AI52!$"0Q"OQ/%<-0P3HMU< #0PQ
M'V#@6(897 X=( $;WSQGD& 0L%BAA4$:=F-2! R$#4*5\=" DV6]A:/_3@4X
MD 25_\0#S& 3OE=8EGII9>*1;3K73SW+_&&%!V/@L@X^"-FS3"-<0!$&(^:X
M.>@_^$A#2@L8=' '-,0AM(XD9$C!12/+-"?>$N5-B!X;ZNDFSB=(D+541 ?P
MD$HX'GJU3SS"J)A DQ'BF"9+0[(12ZK.T9/-)SXX8".%9J)98&8 +,##K=C$
MH^J'(>YU%INXL2I+$@\8<.%*Z'4RS5^YQ?,*0S?R)\$GN:I%#S:=K#9L1!!L
M0DVWSPGV0+"T!EFA2@6\&"9EEF&Y9%E01LB20&">YBJ]V"K%KKT-E!@.H1$#
MQ@XN@XPQ!R_L.'H0/L[T 04-8:P"39X2.X>/_S>G/%+*,N_(U(_'4,B 1B_N
M;'S;>)KNQ*F1;=)4+;!O'; O;OS$4\TG24B0UZRD9@G D$FD<DT\^[BI3SBR
MJ/BOF88]G1D#LW4BB[+,(@1B Q F92I7SV']"@\'#- T8C[$DH[9+RO$@P!P
M$2 77;?M<U=>AFW6@S!6M]FJ:D]V?2_#V 90,+__6(GEPDT[[;5A?QO\CSRI
M)7QFY/;F^+#)J1O4SSOKF&..._C<;) [O7 '119_-&//[*GC8TXRE)#2S#KN
MU".[3/8X,PD84'!A2#G/C??K>43VW.8]WWCBGI8!R,4C;O?$@TTLF@PA0=H"
MWQO 16+'0G7>;?83S_\WPGRB! _E#9 F4YM!P$,2-/$*87 C'C')337PLC^L
M'& "1?)9-3;!O:2LY&]#D$75<),--BR--3H"'VXJTX-_K:0!/O $Q-P4#ZV-
M3B]?BU6]*J*C:R $')O@P0(T%T,)9>XP,SP-"^U5N@*92A.>4EW$[E$.7. A
M#HO(A3MDPAM&A"$*4RB#)+:A."0:IPL9,$$><!%%M9B#$7ZBE*6>L\)/=&(3
M;G2C)CKQ"6'$2X6T8*,FWKB)3O"1C[&0D7/V00]U?&,:L? $&T3B Q[PH 0E
M8"0/AI $-FSB$[*HQC?408\M(O$?^HA'.+ AC%=T(I%)^,$B>= #'TB2DI[_
MB(4PK@&.>- C?K=1"!_?V,8XOJ(:=53C'3N1QSWF<A.:8$,G:"$.3M8%'++P
MQ##?^(EJ+$LW^E#'-#ZA1S=^@AH9=-,^U&&_:!)SF^8\)SKU&$=/8! A*"(E
M.=-YSC:ZD9[&[ 0[ :F/= @#FKHLICP#ZL97^K*3J7-',1"1 @QH(5!>Z8<[
MC.&'+$!A"FNHE,TB]KMMN,,<QJ!$'@ZQBW*4#"&&\@T4H- '9Y34.?JX!SUB
M*M.8WH.9X-3'3',:#UI&;!_BBX<ZP@&.H1(U'.K8:2T-&DB8 C6HX7BJ.(Y*
M2WW8]&HYG2E5(]8/G%Y5ICO-JFY\>M4#'DFL.25K_T^[JM:ULG6L>=L'5]LJ
MUZ[>PVR"G"M>SPI6I6JU'MMP12N:P8Z6FM0<N9@H%";EATHL@QU5!<P\E.&(
M(\" #IDH1SW<$;O>[0,:@J H%Q:AC'GPM;2F/2UJ4ZO:U;*VM:Y]+6P-N@][
MN*,9CT $)98A#Z_@@QU\2L,4:$ %+I#!#XVXA3*D80YVN$,>[V"'.:"!C&2\
M;AF4>$$(YK"*\$S,%GW @O,, 8W'QK:\YCTO>M.KWO6RM[VYD8<R%H&""M0
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'L]Y&0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>rmti-20200915_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rmti-20200915.xsd" xlink:type="simple"/>
    <context id="ib414193a846b4c529904a1fa97557c79_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV80L2ZyYWc6ZWZmOThiNGJjMWRjNDc1Yjk0OWRiM2Y5OTE0MTRmMWQvdGFibGU6MTY4MTM3YjBmNjk1NDgzM2FkOGU5NGJkNDA0NThkZWIvdGFibGVyYW5nZToxNjgxMzdiMGY2OTU0ODMzYWQ4ZTk0YmQ0MDQ1OGRlYl8xLTEtMS0xLTA_78875133-66ad-4c35-b220-7215b7804c8c">0001041024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV80L2ZyYWc6ZWZmOThiNGJjMWRjNDc1Yjk0OWRiM2Y5OTE0MTRmMWQvdGFibGU6MTY4MTM3YjBmNjk1NDgzM2FkOGU5NGJkNDA0NThkZWIvdGFibGVyYW5nZToxNjgxMzdiMGY2OTU0ODMzYWQ4ZTk0YmQ0MDQ1OGRlYl8yLTEtMS0xLTA_cc8eacc3-90ed-4dc0-8bef-853309126c40">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU1_09fe5671-14a0-42cb-ab84-c4cad611d2bb">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMzc_7daa98b9-751b-45bc-b8b2-f186f95b81fb">2020-09-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU4_99e9c7fc-90d8-4449-a55b-9b3b11ad9685">ROCKWELL MEDICAL,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MWJiY2NjZTRjZGEyNDBmNDhmMWNlOTc1NWEzMmIxNTEvdGFibGVyYW5nZToxYmJjY2NlNGNkYTI0MGY0OGYxY2U5NzU1YTMyYjE1MV8wLTAtMS0xLTA_143d8cf9-09d9-4ea3-8ab3-a7708448eefb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MWJiY2NjZTRjZGEyNDBmNDhmMWNlOTc1NWEzMmIxNTEvdGFibGVyYW5nZToxYmJjY2NlNGNkYTI0MGY0OGYxY2U5NzU1YTMyYjE1MV8wLTEtMS0xLTA_6883eddd-208f-48b4-8334-a92c5979156c">000-23661</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MWJiY2NjZTRjZGEyNDBmNDhmMWNlOTc1NWEzMmIxNTEvdGFibGVyYW5nZToxYmJjY2NlNGNkYTI0MGY0OGYxY2U5NzU1YTMyYjE1MV8wLTItMS0xLTA_a125958f-6489-40e3-9bec-3e08fc2319f0">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU5_d44d5b5d-8dbd-48dc-996d-701441cbfcec">411 Hackensack Avenue, Suite&#160;501</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU2_57d0cdf0-0993-45f8-958f-d042c5ff7510">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTYw_7fd06ed4-4a90-411d-b69e-780bf5c9381b">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTYx_948df709-4886-4ada-affa-49dc72472e31">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTYy_58b13ec5-3f42-43a2-af7e-c73883e24467">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTU3_f4e3ff11-97dd-43be-9be2-a440666e0b50">960-9009</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6NzQ5M2UyYzJiNzI2NDQwYmE4NWRiNmM2MmM0MzcwZGUvdGFibGVyYW5nZTo3NDkzZTJjMmI3MjY0NDBiYTg1ZGI2YzYyYzQzNzBkZV8wLTEtMS0xLTA_e96d30a0-3bf4-4124-937b-7a1d161c6384">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6NjhhNmM2YjM0YmIxNDMwZmIxMmM2OTUyNmY2M2RlNTkvdGFibGVyYW5nZTo2OGE2YzZiMzRiYjE0MzBmYjEyYzY5NTI2ZjYzZGU1OV8wLTEtMS0xLTA_31b59ede-1a20-4122-9d2f-07f9ed1848ab">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MGZlYTFhZTg1YjMwNDBlZWE4NGY3OWEwOTc4YzU5NDUvdGFibGVyYW5nZTowZmVhMWFlODViMzA0MGVlYTg0Zjc5YTA5NzhjNTk0NV8wLTEtMS0xLTA_c9585c35-ec24-4fc3-92d5-ff06758e562a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6YzQ1ZDQwNzdiMDU2NGRjZTk1NGFmNzQ4ZGVmYTlhYWYvdGFibGVyYW5nZTpjNDVkNDA3N2IwNTY0ZGNlOTU0YWY3NDhkZWZhOWFhZl8wLTEtMS0xLTA_770898d2-61d9-4a50-b795-b8ddfb29930d">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MTc4MzI0YThlZjUzNGZiODk4NDg0ZjhmZWZlMDg1ZDIvdGFibGVyYW5nZToxNzgzMjRhOGVmNTM0ZmI4OTg0ODRmOGZlZmUwODVkMl8xLTAtMS0xLTA_9938153c-c1bf-41ce-b332-8ba5df113d0d">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MTc4MzI0YThlZjUzNGZiODk4NDg0ZjhmZWZlMDg1ZDIvdGFibGVyYW5nZToxNzgzMjRhOGVmNTM0ZmI4OTg0ODRmOGZlZmUwODVkMl8xLTItMS0xLTA_c3ba7c37-273d-4955-ae06-f0b3966b669d">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGFibGU6MTc4MzI0YThlZjUzNGZiODk4NDg0ZjhmZWZlMDg1ZDIvdGFibGVyYW5nZToxNzgzMjRhOGVmNTM0ZmI4OTg0ODRmOGZlZmUwODVkMl8xLTQtMS0xLTA_54d03a3c-cca6-444c-888d-2af203964152">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib414193a846b4c529904a1fa97557c79_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjZTg0NTEyYzhiZjQ1MzU5MGU5NmIzNjQ4YTY2OGVhL3NlYzpiY2U4NDUxMmM4YmY0NTM1OTBlOTZiMzY0OGE2NjhlYV8xL2ZyYWc6OTVkZWIwNjdmZTBkNDRlNmEyN2IyNGM3MGQ0OWU4MmEvdGV4dHJlZ2lvbjo5NWRlYjA2N2ZlMGQ0NGU2YTI3YjI0YzcwZDQ5ZTgyYV8yMTYz_4daacbf2-25ec-4847-8193-fb559bdc5103">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140635695250840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 15,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ROCKWELL MEDICAL,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">411 Hackensack Avenue, Suite&#160;501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZ*%K66\=\+H/@Y1DZ>ETSQ07FA:9'M2#PIY49M"8TQ-E1=88O3.O:21\*5=
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M,:@W6]5C6)>E:H\_A?<HN9\;[O\2Q0]02P,$%     @ _:(P49>*NQS
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M7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ _:(P420>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #]HC!1SEJH%>\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #]
MHC!1F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( /VB,%%0)49Y/@0  $(0   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #]
MHC!1@ZFE ]0!   R!@  #0              @ &"#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( /VB,%&7BKL<P    !,"   +              "  8$.
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /VB,%&JQ"(6,P$  "("   /
M          "  6H/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #]HC!1
M)!Z;HJT   #X 0  &@              @ '*$   >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #]HC!199!YDAD!  #/ P  $P
M        @ &O$0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(  #Y$@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rmti-20200915.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="rmti-20200915.htm">rmti-20200915.htm</File>
    <File>ex-rmtix20200915xrsxcf.htm</File>
    <File>ex-rockwellxxskibstede.htm</File>
    <File>rmti-20200915.xsd</File>
    <File>rmti-20200915_cal.xml</File>
    <File>rmti-20200915_def.xml</File>
    <File>rmti-20200915_lab.xml</File>
    <File>rmti-20200915_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rmti-20200915.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "rmti-20200915_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rmti-20200915_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rmti-20200915.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20200915_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20200915_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "rmti-20200915.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20200915",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200915.htm",
      "contextRef": "ib414193a846b4c529904a1fa97557c79_D20200807-20200807",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://rockwellmed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20200915.htm",
      "contextRef": "ib414193a846b4c529904a1fa97557c79_D20200807-20200807",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001628280-20-013679-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-013679-xbrl.zip
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M5KBQ$D6O$Q/#[\V*QLVFD&*@33J6-I:!RME-P3MR)Q'R3*2=S@A'&</0V)C
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MK9VN*!0LH.MUM&&0$.KYAR_=_N=G*&[WD(M;.]%GMTPI!7PD_>8(*JBLO*W
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M57NT&2$"IINCH8"SEC1UB=46>.#I[/ Q<B-#KW \]N[GI\8_!?YHW7:)3^W
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MW$QUYF[6,3WS/U15JTUT]LWSL_/=L(Q3G?EETQ1,6O4>U(SF4 *6@BVT\M.
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M\5B%T"1O%-ZP);*B"AZFT)OQ>5PD!(P*3J(P\/@>+E@-VJ]4]IYN5Z\O&LK
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M\_W,JE$A>HZEZ<0L$5-NUD3W[W^\;44Z\ ;U!0U\E9GN6^&LQ".?)7E2>,"
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M@,D  @.7;X5>1M/8C'PO:,AF2A L//Y]X]<W0X%G%VS>)=9,)BC>P)&8<#\
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M? @I?6(_ GV(*F--Q^(P>!71_PM1N)3[U#45MM;D!265=DK[(TE>AVRT/H;
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M6$D5H"!<*SZ70\/ST=;DR"Y;K]CGXOP$9HTG6Y<DRBC?5F-$Q3*CRWB1A(,
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M<W$I=^KG-VWETV47:6M^ONS4]Z'MX>7@K)65^0IMZ>&@%TTZ%^>3]HWCM9M
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M)#"OB#+KDO_R'/SM>C06&$%TH:>JM?Z>5Y:[A??R1_.UCX"_D9/_ F\0IW5
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M]*@K?)K-<++AAI:=[-W!. &6),GL%75=E+<KNJ"7=WMSFY^/%Q[G_2H)[;A
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M_UB*TB/FCD5Z6?^9#P+LFZ)SI?\=HX"P?C-0$+-H+<X;V4PGT^]HQ%IBR Q
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M#&QOID&C1W!>65-CGC",P$C;*G.J\>VW3V2#;W:KU?8-(?<?C@?TT<J' 4Q
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M_^X I@"FA3:6W]*?WGBW^@Y02P,$%     @ _:(P447-@KT% @  :08  !4
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MDNBKXIO]K+,X55]SGN477.B905]ZRQ]N].NS13R_F>GU>]>9CNK=SK*LXK5
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M]YY=;[D=>%Y=G]3NC+K!KDG"F[Q?F*,WS];OQ,M=T-\\^S]02P,$%     @
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M+U!+ 0(4 Q0    ( /VB,%%X8$7MY!$  .Q-   :              "  0
M  !E>"UR;71I>#(P,C P.3$U>')S>&-F+FAT;5!+ 0(4 Q0    ( /VB,%&Y
ME7>T"&\  *WS @ :              "  1P2  !E>"UR;V-K=V5L;'AX<VMI
M8G-T961E+FAT;5!+ 0(4 Q0    ( /VB,%$-8#TAZR   -7^   1
M      "  5R!  !R;71I+3(P,C P.3$U+FAT;5!+ 0(4 Q0    ( /VB,%%=
M(=W_B (  '0)   1              "  7:B  !R;71I+3(P,C P.3$U+GAS
M9%!+ 0(4 Q0    ( /VB,%&,5:71@@$  ,0"   5              "  2VE
M  !R;71I+3(P,C P.3$U7V-A;"YX;6Q02P$"% ,4    " #]HC!11<V"O04"
M  !I!@  %0              @ 'BI@  <FUT:2TR,#(P,#DQ-5]D968N>&UL
M4$L! A0#%     @ _:(P49V-JJ1\"@  TUX  !4              ( !&JD
M ')M=&DM,C R,# Y,35?;&%B+GAM;%!+ 0(4 Q0    ( /VB,%%^*67,LP8
M &0Q   5              "  <FS  !R;71I+3(P,C P.3$U7W!R92YX;6Q0
52P4&      @ "  : @  K[H

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
